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Abstract
Trypanosoma congolense is a principal agent causing livestock trypanosomiasis in 
Africa, costing developing economies billions of dollars and undermining food se-
curity. Only the diamidine diminazene and the phenanthridine isometamidium are 
regularly used, and resistance is widespread but poorly understood. We induced 
stable diminazene resistance in T. congolense strain IL3000 in vitro. There was no 
cross- resistance with the phenanthridine drugs, melaminophenyl arsenicals, oxab-
orole trypanocides, or with diamidine trypanocides, except the close analogs DB829 
and DB75. Fluorescence microscopy showed that accumulation of DB75 was inhib-
ited by folate. Uptake of [3H]- diminazene was slow with low affinity and partly but 
reciprocally inhibited by folate and by competing diamidines. Expression of T. congo-
lense folate transporters in diminazene- resistant Trypanosoma brucei brucei signifi-
cantly sensitized the cells to diminazene and DB829, but not to oxaborole AN7973. 
However, [3H]- diminazene transport studies, whole- genome sequencing, and RNA- 
seq found no major changes in diminazene uptake, folate transporter sequence, or 
expression. Instead, all resistant clones displayed a moderate reduction in the mito-
chondrial membrane potential Ψm. We conclude that diminazene uptake in T. con-
golense proceed via multiple low affinity mechanisms including folate transporters; 
while resistance is associated with a reduction in Ψm it is unclear whether this is the 
primary cause of the resistance.
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1  | INTRODUC TION
Animal African Trypanosomiasis (AAT), also called nagana, is an in-
fection of livestock and wild animal species with African trypano-
somes, principally Trypanosoma congolense, Trypanosoma brucei sspp, 
Trypanosoma vivax and Trypanosoma suis, which is spread by the bite 
of infected tsetse flies. It has a very severe impact on livestock farm-
ing in sub- Saharan Africa, costing billions of dollars in lost agricul-
tural production. AAT therefore affects issues such as food security, 
diet, and rural development, and the livelihood of rural African com-
munities in endemic areas (Giordani et al., 2016). Although Human 
African Trypanosomiasis (HAT), or sleeping sickness, is in rapid de-
cline in most of Africa due to active case finding and rapid treatment 
(Kennedy, 2019; Lehane et al., 2016), AAT remains a very serious 
problem throughout the continent. This is due in no small measure 
because just two old drugs have been the mainstay of AAT treat-
ment for decades: diminazene aceturate (DA) and isometamidium 
chloride (ISM). Resistance to each has been reported from most 
countries in which the disease is prevalent (Giordani et al., 2016), 
and no new drugs have been introduced for over half a century. Yet, 
while there are many studies documenting treatment failures in the 
field, relatively little progress has been made in understanding the 
mechanisms of resistance in the clinically most relevant animal try-
panosome species, T. congolense and T. vivax.
By contrast, much progress has been made in understanding re-
sistance to the suite of drugs used to treat the various manifestations 
of HAT, caused by the T. brucei subspecies T. b. gambiense (in West 
and Central Africa) and T. b. rhodesiense (in East and Southern Africa). 
Most of the resistance mechanisms uncovered for HAT drugs involve 
aspects of drug uptake by the parasite. For instance, pentamidine 
(used for early stage gambiense HAT) and melarsoprol (now mostly 
used for late stage rhodesiense HAT) are internalized by two transport 
proteins in the trypanosome's plasma membrane. The first of these is 
an aminopurine transporter called P2 (Carter & Fairlamb, 1993) en-
coded by the gene TbAT1 (Mäser et al., 1999), the deletion of which 
has been shown to cause a loss of sensitivity to these drugs (Matovu 
et al., 2003). Subsequently, it was shown that a second and more im-
portant determinant for pentamidine- melarsoprol cross- resistance 
is the High Affinity Pentamidine Transporter (HAPT1) (Bridges 
et al., 2007; De Koning & Jarvis, 2001), which was more recently 
shown to be the aquaglyceroporin TbAQP2 (Baker et al., 2012; 
Munday, Settimo, et al., 2015). Rearrangements in the TbAQP2 locus 
were clearly linked to treatment failures, particularly with melarsop-
rol (De Koning, 2020; Graf et al., 2013). Similarly, resistance to ef-
lornithine, used against late- stage gambiense HAT, is associated with 
the loss of an amino acid transporter, TbAAT6 (Alsford et al., 2012; 
Vincent et al., 2010), and resistance to suramin, the first- line drug 
against early- stage rhodesiense HAT, is the result of mutations that 
interfere with its uptake by receptor- mediated endocytosis (Alsford 
et al., 2012; Zoltner et al., 2016, 2020).
In T. congolense, resistance to isometamidium has also been 
attributed to reduced accumulation of the drug (Sutherland & 
Holmes, 1993; Sutherland et al., 1991, 1992; Tihon et al., 2017), 
possibly in part linked to reduced mitochondrial membrane potential 
(Eze et al., 2016; Wilkes et al., 1997), which diminishes sequestra-
tion of cationic drugs into the mitochondrion (Alkhaldi et al., 2016; 
Lanteri et al., 2008; Stewart et al., 2005)— the likely site of drug ac-
tion. For DA, it has been shown in the T. b. brucei model that it is al-
most exclusively taken up by the P2/TbAT1 transporter (De Koning 
et al., 2004) as it is a very poor substrate for the HAPT1/TbAQP2 
transporter (Munday et al., 2014; Teka et al., 2011). It was subse-
quently proposed that the same mechanism would apply in T. congo-
lense, with an adenosine transporter designated TcoAT1 mediating 
DA uptake, and DA resistance being the result of specific single- 
nucleotide polymorphisms (SNPs) that could be used to screen for 
resistance (Delespaux et al., 2006; Delespaux & De Koning, 2013; 
Vitouley et al., 2011). However, expression of the putative TcoAT1 in 
a multi- drug resistant T. b. brucei clone, B48, showed that this gene 
encoded a P1- type broad specificity purine nucleoside transporter 
with no ability to transport diminazene (Munday et al., 2013), and 
genomic analysis has shown that there is no direct ortholog of the 
P2/TbAT1 transporter in the genome of T. congolense. Regrettably, 
this has left us still without any insights into the urgent problem of 
DA resistance in animal African trypanosomiasis.
One urgent question beyond that of the resistance mechanism 
is that of cross- resistance with isometamidium, which has been re-
ported repeatedly from the field (Mamoudou et al., 2008; Sinyangwe 
et al., 2004), but inconsistently, as others report no cross- resistance 
and it used to be a rare occurrence (Giordani et al., 2016; Joshua 
et al., 1995; Sow et al., 2012). Clearly, it is possible that trypano-
somes may have developed resistance to both drugs independently 
over the decades and are now resistant to both by separate mech-
anisms. Thus, it is currently unclear whether other diamidine drugs 
should be considered for novel drug development for AAT because 
of the risk of cross- resistance with DA. This adds to the many rea-
sons why it is important to understand the mechanism of DA re-
sistance in animal- infective trypanosomes, alongside the need to 
identify screening tools for AAT drug resistance to assess the real 
levels of resistance in the field.
Here, several of these issues are addressed in an attempt to de-
velop a hypothesis for DA resistance in T. congolense, and we report 
that DA resistance is not linked to reduced drug accumulation in T. 
congolense, nor necessarily to cross- resistance with isometamidium. 
However, we present evidence of a lower mitochondrial membrane 
potential in the resistant clones, which is stable and somehow linked 
to DA resistance, although it is more likely to be the result of the 
adaptation to DA than the principal cause of the resistance in itself, 
as the degree of the mitochondrial membrane depolarization is lim-
ited, and the cells were not cross- resistant to most cationic drugs. 
Moreover, mitochondrial accumulation of the close DA analog DB75 
did not appear to be diminished in the diminazene- resistant cells. 
Genomic analysis identified missense mutations in two vacuolar- 
type Ca2+- ATPases that may have regulatory functions in mitochon-
drial metabolism. In sharp contrast to T. brucei spp, uptake of [3H]- DA 
by T. congolense was low affinity and inefficient and involves, at least 
in part, folic acid transporters.
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2  | RESULTS
2.1 | In vitro induction of diminazene aceturate 
resistance in T. congolense
Four cultures of T. congolense TcoIL3000 were grown and passaged 
in parallel; a control without added drug and three separate, inde-
pendent cultures in the presence of DA for adaptation to increasing 
concentrations, from which ultimately six clonal lines were obtained.
Resistance was very slow to develop, as documented in Figure S1. 
At the end of the adaptation, after 227 passages, the control culture 
tolerated 50 nM DA, whereas all the adapted cultures tolerated a 
maximum level of 800 nM DA, in what appeared to be at least two 
steps, with an initial plateau at 550 nM, where the strains were as-
sessed for their level of DA resistance and cross- resistance pattern. 
At the 550 nM point, final clones were obtained from each of the 
parallel cultures, by limiting dilution. In this study we used one clone 
obtained from original line 4 (4C2), and two clones each from lines 5 
(5C1, 5C2) and 6 (6C1, 6C3).
At the point of adaptation to 550 nM, the level of DA resis-
tance and the extent of any cross- resistance with the diamidine 
drugs pentamidine and DB829, and with oxaboroles AN7973 and 
SCYX7158, were tested using an assay based on the viability dye 
Alamar blue (resazurin), in which live trypanosomes (but not dead 
ones) reduce blue and non- fluorescent resazurin to pink, fluores-
cent resorufin. This assay yields a fluorescent output that is propor-
tional to the number of cells in the well (Gould et al., 2008). The 
results, summarized in Figure 1a, show that all the DA- Res strains 
display highly similar drug sensitivity patterns. Resistance to DA, 
as measured in this assay, was ~2.3– 3- fold, and highly significant 
(Figure 1a for fold differences and p values, Table 1 for EC50 values). 
No cross- resistance with pentamidine was observed, but the level 
of resistance to DB829, a structurally closer analogof DA, mirrored 
the resistance profile of DA very closely, demonstrating that cross- 
resistance to diamidines is not inevitable, but observed only with 
close structural analogs. Importantly, there was no cross- resistance 
with isometamidium, nor with either of the oxaboroles tested, 
AN7973 and SCYX7158.
To further investigate the limits of cross- resistance with other di-
amidines, a series of bis- benzofuran analogs (Bakunova et al., 2007) 
were tested (Table 1). These analogs were chosen to explore the 
effect of variable linker length between the benzofuramidine end 
groups, varying inter- amidine distance as well as the flexibility of the 
molecule. All the benzofuramidines displayed low micromolar activ-
ity (Table 1), and there was no cross- resistance with DA (Figure 1b). 
These results clearly show that the cross- resistance phenotype is 
F I G U R E  1   In vitro cross- resistance 
pattern of clones from three 
independent diminazene- adapted 
cultures with EC50 values given relative 
to that for the control strain, IL3000, 
adapted to growth in 550 nM DA. (a) 
Cross- resistance to DB829 but not 
pentamidine, isometamidium, AN7973 
or SCYX7158 was observed (n = 5– 9). 
(b) Cross- resistance to a series of bis- 
benzofuramidines was investigated— 
none of the strains were more than 
marginally resistant or sensitized to these 
compounds and the average EC50 of the 
5 resistant strains was in all cases very 
close to the value for the IL3000 control. 
All structures are displayed in Table 1. 
Statistical significance between EC50s of 
a resistant line and the IL3000 control 
was determined using Student's unpaired, 
two- tailed t- test; *p < .05; **p < .01; 
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very narrow and that many diamidines are still potentially useful for 
the treatment of DA- resistant AAT.
The DA- resistance of the five DA- resistant clones was then in-
creased via further in vitro exposure until they could tolerate growth 
at 800 nM DA, and attempts to raise the resistance level further were 
not immediately successful; all subsequent experiments were done 
with the clones adapted to 800 nM DA. The in vitro growth rates of 
these final strains consistently appeared to be slightly slower than that 
of the drug- sensitive parental strain (Figure 2), although this reached 
statistical significance only for the 48 hr and 64 hr points of clones 
5C2 and 6C1 (p < .05, unpaired student's t- test). The EC50 values, at 
~2.2 µM, were similar for all clones but significantly higher than when 
they were measured before the cloning, at 550 nM DA medium con-
centration. This level of resistance, approximately ninefold compared 
with IL3000 WT (0.244 ± 0.004 µM in parallel experiment, n = 4, 
p < .00001, t- test, for all DA- RES strains versus IL3000 WT), was sta-
ble for at least 3 months of in vitro culturing in the absence of drug 
pressure (Figure 3a). Cross- resistance to DB829 was again observed in 
all clones (ca. fivefold), whereas sensitivity to pentamidine was identi-
cal in all clones including wildtype IL3000. Interestingly, sensitivity to 
AN7973 was slightly but significantly higher in most DA- Res clones 
(Figure 3d). Cross- resistance with phenanthridines isometamidium, 
and ethidium bromide, as well as with the melaminophenyl arsenical 
cymelarsan, was also tested for selected clonal lines. A slight loss of 
sensitivity to phenanthridines was consistently observed and reached 
significant (but lesser than twofold) levels in some clones. No change in 














































































































































































































































































































































































































































































































F I G U R E  2   Growth curve of diminazene- sensitive TcoIL3000 
and 5 different diminazene aceturate- resistant T. congolense clones. 
The cells were cultured at 34°C and 5% CO2 in TcBSF- 3 medium 
for up to 64 hr in a six- well plate and counted periodically using a 
hemocytometer. The graph shows the average and SEM of three 
independent repeats performed with different cultures. When the 
error bars are not shown they fall inside the symbol
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2.2 | In vivo confirmation of cross- resistance profile
In order to confirm that the in vitro pattern of cross- resistance held 
up for in vivo infections, including for a field- derived DA- resistant 
strain, we infected groups of six mice that were treated i.p. with ei-
ther DB829 (Figure 4a) or AN7973 (Figure 4b), using single doses of 5, 
10, or 20 mg/ kg body weight (two separate independent experiments 
with each drug, each experiment n = 6). For the resistant field isolate, 
we used stain KONT2/151 (Mamoudou et al., 2006). IL3000 was more 
virulent than KONT2/151, as is often observed with cultured trypano-
some strains, and was sensitive to both DB829 and AN7973. DB829 
delayed parasitemia and death with a dose of 10 mg/kg and was 
F I G U R E  3   Stability of resistance phenotype in diminazene- adapted T. congolense clones. EC50 values were obtained using the Alamar 
blue assay. (a) Diminazene aceturate; (b) Pentamidine; (c) DB829; (d) AN7973; (e) Cross- resistance with phenanthridines ethidium and 
isometamidium and melaminophenyl arsenical cymelarsan. All bars represent the average and SEM of four independent determinations. 
Statistical significance between EC50s of a resistant line and the IL3000 control was determined using Student's unpaired, two- tailed t- test; 
*p < .05; **p < .01; ***p < .001; ****p < .0001. IL3000 = wild- type control; “Clone A” = grown in the presence of 800 nM diminazene; “Clone 
B” = passaged for 3 months in the absence of diminazene drug pressure but previously grown in 800 nM DA. In panel E, all clones had been 
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curative at 15 and 20 mg/kg, whereas AN7973 delayed parasitemia at 
5 mg/kg and cured with 10 or 20 mg/kg. The DA- resistant field isolate 
was equally sensitive to the oxaborole but resistant to DB829, as even 
the highest dose, 20 mg/kg, merely delayed the onset of parasitemia.
2.3 | Screen for potential diminazene transport 
inhibitors by DB75 fluorescence microscopy
In T. b. brucei, fluorescent diamidines such as DB75, a close structural 
analog of DA and DB829, have previously been used to monitor 
uptake and cellular distribution of such compounds (Stewart 
et al., 2005). In those experiments, the rate at which the kinetoplast 
(first) and the nucleus (second) became visible in the blue wavelengths 
(λ = 405/435 nm for excitation and emission, respectively) was 
much delayed in resistant strains, and in the presence of transport 
inhibitors (Stewart et al., 2005). Here, the technique was used to 
screen for potential transport substrates that competitively inhibit 
the uptake of the DB75 in animal trypanosome species. The utility 
of the technique was first confirmed in ex vivo T. b. brucei in mouse 
blood. Murine blood cells did not appear to significantly take up 
10 µM DB75, ensuring a low background, but in T. b. brucei, parasite 
F I G U R E  4   In vivo analysis of drug sensitivity for drug sensitive T. congolense clone IL3000 and diminazene resistant isolate T. congolense 
KONT2/151. (a) Infected mice were treated with the indicated doses of DB829 or with vehicle (no- drug controls). Each group consisted of 
six mice. Parasitemia was determined daily from blood taken from tail- pricks and shown as average ± SEM. Mice infected with IL3000 are 
represented by solid symbols and lines; KONT2/151 by open symbols and dotted lines. (b) Like (a), but the treatment was with AN79373. 
The results shown are single experiments but representative of two very similar experiments with essentially the same outcomes
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outlines would become visible after 4 min, followed by kinetoplasts at 
5– 6 min and finally nuclei were faintly stained by 8 min and bright by 
15 min. These stages were all observed and scored in the presence of 
potential inhibitors. As expected, based on current T. brucei models 
(De Koning et al., 2004; Teka et al., 2011), the polyamines putrescine, 
spermine and spermidine (500 µM) had no discernible effect on 
DB75 staining, although the polyamine transporters of Leishmania 
spp and T. cruzi have been implicated in possible pentamidine uptake 
(Basselin et al., 1996; Díaz et al., 2014; Hasne & Ullman, 2005). By 
contrast, DA and the shorter pentamidine analog propamidine both 
dose- dependently delayed DB75 fluorescence (Table S1); both are 
known substrates of the TbAT1/P2 aminopurine transporter (De 
Koning & Jarvis, 1999, 2001) that is the sole uptake mechanism for 
DB75 in T. brucei (Ward et al., 2011).
Because of the involvement of the TbAT1/P2 purine transporter 
in DA uptake by T. b. brucei, we tested a range of purine and pyrimi-
dine nucleosides and nucleobases for delaying DB75 cell entry in T. 
congolense, using the IL3000 WT cell line. Adenine and adenosine did 
not appear to slow DB75 fluorescence up to 1 mM, but were toxic to 
the cells at the concentrations of 200 µM and above. Other purines 
(inosine, guanosine, hypoxanthine, guanine, xanthine) or pyrimidines 
(uridine, cytidine, thymidine, uracil, cytosine) likewise failed to inhibit 
DB75 uptake; moreover, polyamines and amino acids (500 µM) were 
similarly ineffective in this assay (Table S1). Glycerol was also tested 
at up to 20 mM because some diamidines including pentamidine are 
taken up by an aquaglyceroporin in T. brucei (Alghamdi et al., 2020; 
Baker et al., 2012), but the data indicated that glycerol also does 
not compete for the T. congolense DB75 transporter. However, the 
diamidines DA and, particularly, propamidine and pentamidine dose- 
dependently (100– 500 µM) delayed DB75 fluorescence, and so did 
folic acid, from 200 to 500 µM (Figure 5). T. vivax was also assayed 
by this method and similar results were found, with no effect from 
a series of purines and pyrimidines, glycerol, and the cationic amino 
acids lysine and arginine, but dose- dependent inhibition by pentam-
idine and DA. For this parasite, there appeared to be some minor 
fluorescence delay in the presence of 500 µM folic acid or biopterin, 
but not at lower concentrations, and possibly in the presence of the 
polyamines spermidine and putrescine (Table S1).
2.4 | Uptake of [3H]- Diminazene by  
DA- sensitive and - resistant T. congolense clones
In T. brucei, resistance to DA is linked to loss of the TbAT1/P2 
transporter (De Koning et al., 2004; Graf et al., 2013; Matovu 
et al., 2003). While T. congolense does not have an equivalent trans-
porter (Munday, Tagoe, et al., 2015), drug resistance in trypanoso-
matids has very often been associated with the loss of transporters 
at the plasma membrane (De Koning, 2020; Landfear, 2008; Munday, 
Settimo, et al., 2015) and we thus investigated whether uptake of 
[3H]- DA was altered in the resistant clones.
Initial experiments with various concentrations of [3H]- DA, trying 
to standardize linear uptake conditions, were unsuccessful. Uptake 
was very slow, the label displayed high background from binding to 
the outside of the cell and a true linear phase of uptake could not be 
established with the requisite level of confidence and reproducibil-
ity. Therefore, accumulation of 0.1 µM [3H]- DA was monitored over 
30 min in IL3000 and two of the derived DA- resistant clones, 4C2 
and 6C3. This showed that even over half an hour there was no clear 
difference in the rate of accumulation of [3H]- DA in any of the three 
cell lines and that resistance is therefore very unlikely to be the result 
of induced changes in drug uptake rate (Figure 6a). Indeed, monitor-
ing of DB75 uptake, quantified as incubation time required for stain-
ing of nucleus and kinetoplast to become detectable by fluorescence 
F I G U R E  5   DB75 fluorescence in ex vivo T. congolense trypomastigotes. Parasites were obtained from infected mice and incubated with 
10 µM DB75. Fluorescence was monitored under an Axiosope fluorescence microscope (Zeiss) at an excitation wavelength of 330 nm and 
an emission wavelength of 400 nm. Images were obtained with Openlab imaging software (Improvision, Coventry, UK). The brightfield and 
fluorescence images shown were obtained after 12 min incubation, with the nucleus (N) and kinetoplast (K) of two parasites in the left- hand 
panel visible as blue spots (no inhibitor control) and no fluorescence in the right- hand panel (500 µM DA). These images are representative of 
similar images taken in approximately 2 dozen such experiments
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F I G U R E  6   Investigation into the uptake of diminazene by T. congolense. (a) Uptake of 0.1 µM [3H]- DA by IL3000 and two derived 
DA- adapted clones. Uptake of DA was monitored for 30 min in in vitro grown cells of T. congolense IL3000, 4C2 and 6C3. There were no 
statistically significant differences between the three strains at any of the timepoints. (b) Efflux of [3H]- DA from T. congolense IL3000 and 
from clone 4C2, after loading with 0.1 µM [3H]- DA for 30m min, followed by a wash into fresh assay buffer. Samples were taken at the 
indicated time points after resuspension into fresh buffer. The data presented are the average of each time point of four independent 
experiments, each performed in triplicate. The two slopes, calculated by linear regression, were not significantly different from each 
other (p = .84, F- test), nor significantly different from zero (p = .14 and .46 for IL3000 and 4C2, respectively). (c) IL3000 parasites were 
isolated from mice and incubated with 0.1 µM [3H]- DA with and without 250 µM unlabeled DA. (d) IL3000 parasites from culture were 
incubated with 0.1 µM [3H]- DA label in the presence or absence of 100 µM DA, 100 µM pentamidine (PMD), 100 µM DB829 or 1 mM 
folic acid. (e) Uptake of 0.1 µM [3H]- DA by bloodstream forms of T. b. brucei clone B48 transfected with TbAT1 without inhibitor or in the 
presence of 250 µM DA or 1 mM adenosine (Ado). (f) Uptake of 0.1 µM [3H]- DA by T. congolense IL3000 from culture, in the presence 
and absence of 1 mM folic acid, expressed as % of uptake in the absence of folic acid at 30 min. The average and SEM of six independent 
experiments, each performed in triplicate, is shown. (g) T. congolense IL3000 from culture were incubated with 0.1 µM [3H]- DA for 20 min 
with either no inhibitor, 1 mM folic acid, 100 µM pentamidine, or both together. The level of inhibition was virtually identical with either of 
the two inhibitors, but significantly higher (p < .05) when the medium contained both. Bars represent the average and SEM of a triplicate 
determination. (h) Uptake of 0.1 µM [3H]- pentamidine by T. congolense IL3000 from culture in the presence or absence of 1 mM pentamidine 
(PMD) or diminazene aceturate (DA). One representative experiment in triplicate is shown. (i) Uptake of 0.1 µM [3H]- folic acid by T. 
congolense IL3000 from culture, and the effects of 1 mM folic acid or 1 mM DA. One representative experiment in triplicate is shown. All 
experiments were performed in triplicate and the average and SEM are shown. When error bars are not shown, they fall inside the symbol. 
Statistical significance was calculated using Student's unpaired t- test: *p < .05; **p < .01; ***p < .001












































































































































































































































































10  |     CARRUTHERS ET Al.
microscopy, also showed no difference between IL3000 and DA- 
resistant clone 6C3, at either 1 or 10 µM DB75; lower concentrations 
did not produce detectable staining in either cell line.
Nor was there significant efflux from the cells, after preincuba-
tion with [3H]- DA for 30 min followed by incubation of up to 30 min 
in fresh medium without label or diminazene. Although the slope of 
both the IL3000 WT and the 4C2 clone trended downwards, in each 
of four such experiments the slopes were not significantly different 
from zero, nor different from each other (F- test, p > .05). Figure 6b 
shows the average of four experiments, which still shows a non- 
significant downward trend and no difference between the slope of 
the sensitive and resistant lines. In order to better understand why 
DA- resistance in T. congolense, in contrast to T. b. brucei, is not asso-
ciated with loss of import or gain of efflux function, the mechanism 
by which DA is internalized by T. congolense was further investigated.
Uptake of 0.1 µM [3H]- DA was poorly saturable by even a large 
excess of unlabeled DA (Figure 6c), indicating that DA enters T. con-
golense by a low affinity and/or non- saturable process. Indeed, out 
of several potential inhibitors or substrates of the DA uptake, the 
process was consistently (but always partially) inhibited by 100 µM 
pentamidine, 1 mM folate, and 100 µM DB829 (Figure 6d). This is 
in sharp contrast to DA uptake in T. brucei which is completely sat-
urable and 100% inhibited by a competitive substrate of the TbAT1 
transporter (Figure 6e). The inhibition with folate was confirmed 
and quantified in a series of experiments with added time points, 
and found to be highly significant (Figure 6f). Moreover, in a sepa-
rate experiment it was tested whether the inhibition by folate and 
pentamidine was additive and the data indicated that this was the 
case (Figure 6g), suggesting that in T. congolense DA is taken up by 
at least two separate low affinity transporters, one sensitive to fo-
late and another that is sensitive to pentamidine. However, it must 
be noted that the inhibition by both compounds was modest in this 
experiment and that the joint administration still did not inhibit [3H]- 
DA uptake by even 50%. The complete lack of cross- resistance with 
pentamidine, despite high concentrations of pentamidine partially 
inhibiting DA uptake, is consistent with DA resistance not being the 
result of changes in its uptake rate. Indeed, the overlap in transport 
mechanisms of DA and pentamidine was even more clear from the 
inhibition of [3H]- pentamidine uptake by DA in wild- type IL3000 
(Figure 6h). To further investigate whether (a) folate transporter(s) 
might contribute to DA uptake in T. congolense, we measured the 
uptake of [3H]- folate and found this to be partially inhibited by 1 mM 
DA (Figure 6i).
2.5 | T. congolense folate transporters are engaged 
in diminazene uptake
Three genes encoding putative folate transporters of T. congolense 
were identified via homology searches in TriTrypDB in the original T. 
congolense IL3000 genome and amplified by PCR with Phusion proof- 
reading polymerase from IL3000 and from the DA- resistant isolates 
KONT2/133 and KONT2/151 (sequences, GeneIDs, and GenBank 
accession numbers in Table 2); all three strains are Savannah- type 
T. congolense. The genes were cloned into pGEM- T Easy for amplifi-
cation in E. coli and for each gene at least four independent clones 
were sequenced. The gene sequences from the two KONT strains, 
both from Cameroon, were almost identical to each other, but dis-
played some SNPs relative to IL3000 (Table 3). For folate trans-
porter 1 (TcoFT1, 592 aa) there were two identical, conservative 
SNPs of IL3000 alanine to KONT serine (positions 49 and 331). For 
FT2 (640 aa), there were eight shared non- synonymous SNPs in the 
two KONT strains and one unique one in each, and for FT3, both 
KONT strains carried the same 15 amino acid changes relative to 
IL3000 (Fig. S2); a table with the percentage identity and similarity 
between these genes is included in Table S2. The genes were cloned 
into the pHD1336 expression vector and transfected into T. b. bru-
cei strain B48. This clonal line lacks both the TbAT1/P2 transporter 
and a wild- type TbAQP2 gene, and is thus highly resistant to DA, the 
furamidines, pentamidine, and melaminophenyl arsenicals (Bridges 
et al., 2007; Munday et al., 2014; Ward et al., 2011). As the sensitiv-
ity to these drugs is completely restored upon re- introduction of the 
transporters (Alghamdi et al., 2020; Munday et al., 2014; Munday, 
Tagoe, et al., 2015) this is an ideal system to test potential diamidine 
transporters from other kinetoplastids. Clonal lines were obtained 
by limiting dilution; the correct integration of the expression con-
structs was verified by PCR.
Expression of the T. congolense folate transporters in T. b. brucei 
B48 confirmed that these transporters have some capacity to take 
up diamidines, but not the oxaborole AN7973 (Figure 7). Only FT2 
of IL3000 did not significantly sensitize to any of the drugs tested, 
although its diamidine EC50 values also trended to be lower than the 
control (B48 transfected with the “empty vector”). Sensitization to 
DA and DB829 was almost identical, but only the FT2 transporters of 
the KONT strains significantly sensitized to pentamidine. In all cases, 
the sensitization was modest, reaching ~50% with DA and DB829, 
and <40% for pentamidine, which is consistent with the transport 
experiments with TcIL3000, in that the transporters appear to dis-
play significant and yet very limited diamidine uptake capacity. For 
comparison, the expression of TbAT1 in B48 cells, using the same ex-
pression vector and assays, resulted in ~200- fold sensitization to DA 
TA B L E  2   GenBank Accession Numbers of the T. congolense 
folate transporter genes
FT1 FT2 FT3
KONT133 MT782654 MT782655 MT782657
KONT151 MT782654 MT782656 MT782657
TA B L E  3   Number of non- homologous SNPs in T. congolense 
folate transporter genes, relative to IL3000
FT1 FT2 FT3
KONT133 2 9 15
KONT151 2 8 15
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and pentamidine instead of twofold (Munday, Tagoe, et al., 2015). 
The data presented in Figure 7 do not suggest that the two KONT 
strains are DA resistant because of changes in DA uptake— or at least 
not by their folate transporters. With respect to DA and DB829, the 
IL3000 and KONT FT1 and FT3 performed identically, but the KONT 
FT2 clearly sensitized stronger than the IL3000 FT2.
2.6 | The mitochondrial membrane potential is 
diminished in DA- resistant T. congolense clones
As DA resistance is apparently not linked to changes in DA up-
take, it was hypothesized that an intracellular rather than a cell 
surface change must be responsible for the resistance phenotype. 
Moreover, DA is a DNA minor grove binder, and resistance arising 
due to mutations in a target protein is therefore not expected. Our 
observations with DB75 fluorescence microscopy showed that such 
drugs accumulate first in the kinetoplast, as reported for other spe-
cies (Basselin et al., 2002; Stewart et al., 2005). This requires rapid 
uptake into the mitochondrion, which is driven by the mitochondrial 
membrane potential Ψm as DA, DB75, and other diamidines are di-
cations. We therefore investigated whether Ψm was altered in the 
resistant cell lines. Fluorescence microscopy after DAPI staining 
confirmed that the kinetoplast was present and did not appear al-
tered or damaged in the DA- resistant clones (Fig. S3).
It is already well established that (di)cationic trypanocides that 
accumulate in the trypanosome's mitochondrion cause a reduction 
in Ψm, both through the very fact that they are cations, and through 
disruption of mitochondrial processes (e.g. Alkhaldi et al., 2016; 
Fueyo Gonzalez et al., 2017; Ibrahim et al., 2011; Lanteri et al., 2008). 
For instance, pentamidine has been shown to act as a cationic 
uncoupler of oxidative phosphorylation in isolated rat liver mito-
chondria (Moreno, 1996). However, the more important question 
here was whether, as (part of) the adaptation to DA, the cells had 
F I G U R E  7   Drug sensitivity profile of T. b. brucei strain B48 (Tbb Control) and the same strain transfected with folate transporters 1- 3 
(FT1- 3) of IL3000 (S), KONT2/133 (R1) or KONT2/151 (R2). EC50 values were determined using the Alamar blue assay. Bars represent the 
average and SEM of three independent experiments. Significant differences relative to the Tbb Control were calculated using Student's 
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permanently lowered their Ψm, as previously reported for isomet-
amidium (Eze et al., 2016; Wilkes et al., 1997). The DA- Res parasites 
did present flow cytometry profiles that had shifted significantly to 
lower fluorescence and were broader than the control IL3000 cells 
(Figure 8a). For quantification, the peak of the IL3000 profile was set 
at 80 Arbitrary Units (AU). Taking the percentage of cells with fluo-
rescence >80 AU as a measure for Ψm (Fueyo Gonzalez et al., 2017; 
Ibrahim et al., 2011), a highly significant decrease was found in all 
four DA- Res cell lines tested, although the extent of the Ψm de-
crease was not identical in all cell lines (Figure 8b).
2.7 | Diminazene causes mitochondrial lesions
In order to further assess the T. congolense mitochondrion as the 
target for diminazene, and as a potential contributor to diminazene 
resistance, culture of IL3000 and of 6C3 were grown for 4h or 8 hr 
in the presence and absence of 1.5 µM DA. The cells were harvested 
at the indicated times and processed for transmission electron 
microscopy (TEM). DA caused substantial lesions in mitochondria of 
IL3000 at 4 hr (compare Figure 9a,b) and 8 hr (compare Figure 9e,f); 
large parts of the mitochondria of the DA- exposed cells became 
electrolucent (white arrowhead in Figure 9b), with a vacuolar 
appearance (alterations indicated by black arrows), with some with 
electrondense material within the mitochondrial lumen (arrowhead 
in Figure 9f). By contrast, the mitochondria in the control cells 
remained quite electron dense, and clearly membrane- delineated. 
For the 6C3 cells, the mitochondria looked unchanged after 4h of 
DA- exposure, with very intact, very electron dense kinetoplasts 
(where captured in the frame) and clear membranes (Figure 9c,d). 
After 8 hr of continued exposure to DA, intact mitochondrial 
structures could still be seen in most cells, but lesions had started to 
appear in some of them (Figure 9g,H; arrows), and a less structured 
kinetoplast (white arrow).
2.8 | Genomic analysis of DA resistance
DA- resistant T. congolense were analyzed for SNPs and indels by 
Illumina paired- end whole- genome sequencing. Across the four 
samples (wild type and DA- resistant clones 4C2, 5C1, and 6C3), there 
were a total of 158,396 SNPs and 28,640 indels (see Files S1 and S2 for 
the statistics on SNPs and indels, respectively). Of the indels, 20,107 
were insertions, while the remaining 8,533 were predicted deletions. 
Both datasets were filtered, firstly to remove mutations occurring in 
all four samples, as these are clearly not related to drug resistance, 
F I G U R E  8   Mitochondrial membrane potential in IL3000 and 4 diminazene- resistant clones determined by flow cytometry. (a) Sample 
profiles for TMRE fluorescence of 10,000 cells was obtained on a FACSCalibur flow cytometer, using the FL2- height detector. Sample 
graphs of the IL3000 DA- sensitive parental strain and the 6C1 DA- Res clone are given. (b) Average (and SEM, n = 3) percentage of cells with 
a fluorescence >80 A.U. in the analysis for IL3000 and 4 DA- Res clones. Significant differences with the sensitive control are indicated with 
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and subsequently to obtain lists of high, moderate, and low impact 
(as described in the methods) mutations in protein encoding regions 
(5,263 SNPs and 541 indels) (Table S3, worksheets “SNPs- HIGH- 
MODERATE- LOW” and “Indels- HIGH- MODERATE- LOW”). Once 
mutations that occurred in genes predicted to encode variant surface 
glycoproteins (VSGs), expression site- associated genes (ESAGs) and 
retrotransposon hot spot (RHS) proteins were removed, there were 
19 high impact SNPs (Table S3, worksheet “SNPs- Hi- filtered”) and 192 
F I G U R E  9   Transmission electron micrographs of T. congolense strains IL3000 and 6C3 after incubation of 4h or 8 hr with or without 
1.5 µM DA. (a) IL3000, no drug control, 4 hr. (b) IL3000, +DA, 4 hr. (c) 6C3, no drug control, 4 hr. (d) 6C3, +DA, 4 hr. (e) IL3000, no drug 
control, 8 hr. (f) IL3000, +DA, 8 hr. (g) 6C3, no drug control, 8 hr. (h) 6C3, +DA, 8 hr. Black arrows indicate electron lucent vacuoles in 
mitochondria and black arrowhead electrondense structure in the mitochondria matrix. White arrowhead indicates an electronlucent 
mitochondrion, and a white arrow indicates a less structured kinetoplast. All scale bars are 1 µm; ag, agranular or secretory reticulum; FP, 
flagellar pocket; k, kinetoplast; N, nucleus; M, mitochondrion (Vickerman, 1969).
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high impact indels (Table S3, worksheet “Indels- Hi- filtered”), in addition 
to 1,693 moderate impact SNPs (Table S3, worksheet “SNPs- Mod- 
filtered”) and 42 moderate impact indels (Table S3, worksheet “Indels- 
Mod- filtered”) predicted to result in non- synonymous mutations for 
the former, and in- frame deletions/insertions for the latter. Due to 
the previously described correlation between resistance to the related 
compound isometamidium chloride (a fusion molecule of ethidium and 
diminazene) and reduced mitochondrial membrane potential (Wilkes 
et al., 1997), as well as reduced potential observed in the DA- resistant 
cell lines, data were mined to identify genes that could be involved 
in maintaining or generating this membrane potential. Two copies 
of a vacuolar- type Ca2+- ATPase (TcIL3000.A.H_000569200 and 
TcIL3000.A.H_000569400) harbored missense mutations in all three 
resistant lines (TcIL3000.A.H_000569200: A109T in clones 4C2 and 
F I G U R E  9   (Continued)
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6C3; TcIL3000.A.H_000569400: G855E in clones 4C2 and 5C1). No 
further candidates were found. Two mis- sense mutations were found 
in folate transporter TcIL3000.A.H_000597400 (A132S and N131Y, 
both in clone 4C2 only, both heterozygous) and another two in folate 
transporter TcIL3000.A.H_000597700 (L122R in 4C2 and F371C in 
clone 6C3; both heterozygous). No mutations were found in the other 
folate or pteridine transporters. Mis- sense mutations were also found in 
several copies of an amino acid transporter (TcIL3000.A.H_000388400, 
TcIL3000.A.H_000388500, & TcIL3000.A.H_000388600), a putative 
plasma- membrane choline transporter (TcIL3000.A.H_000774600) 
and two copies of a mitochondrial chaperonin HSP60 gene 
(TcIL3000.A.H_000771700 & TcIL3000.A.H_000772600) (Table S3, 
worksheet “SNPs- HIGH- MODERATE- LOW”).
2.9 | Transcriptomics analysis of diminazene  
resistance
To ascertain whether differential gene expression could explain in-
creased levels of resistance to diminazene, three replicates of the 
wild- type parental line, as well as three replicates of each independ-
ent resistant clone, were subjected to transcriptomic analysis by 
Illumina paired- end sequencing. Data were processed as described 
in the methods, resulting in transcript abundances for 9,360 T. con-
golense genes (Table S3, worksheet “RNAseq_all”). Data were fil-
tered to obtain differentially expressed genes relative to wild- type 
(q value ≤.05), resulting in 274, 247, and 265 genes identified as being 
significantly differentially expressed in DA- resistant clones 4C2, 
5C1, and 6C3, respectively, with 120 of these genes being common 
to all three clones (Figure 10). Genes were then filtered to remove 
VSGs, ESAGs, and RHS proteins, resulting in a final list of 61 genes, 
of which 15 were annotated as hypothetical (Table S3, worksheet 
“RNAseq_filtered”).
One the most significant changes was downregulation of an 
array of H4 histone encoding genes (mean Log2 fold change: −7.842) 
(Table S3, worksheet “RNAseq_DOWN”). Furthermore, there 
was significant downregulation of a putative protein involved in 
elongation of very long fatty acids (TcIL3000.A.H_000436100.1; 
mean Log2 fold change: −6.526) and a putative ZIP Zinc trans-
porter that is, however, indicated as a possible pseudogene 
(TcIL3000.A.H_000205900.1; mean Log2 fold change: −4.099). 
Other downregulated genes of note included a cysteine peptidase, 
as well as four hypothetical proteins (TcIL3000.A.H_000205700.1, 
000206000.1, 000429100.1 and 000429200.1) for which ex-
pression was entirely abolished in all resistant clones. None of 
the hypothetical proteins were found to contain a recognized do-
main using the SMART (Letunic & Bork, 2018), interpro (Hunter 
et al., 2009), and pfam (El- Gebali et al., 2019) tools. Not all of these 
may be equally relevant because the locus of five genes from 
TcIL3000.A.H_000205600.1 to TcIL3000.A.H_000206000.1 were 
all extremely downregulated and this includes a Histone H4, three 
hypothetical proteins that are not related to each other, and the Zip 
Zinc Transporter mentioned above.
There were only 13 significantly differentially expressed genes 
exhibiting a Log2 fold change of >1.0 in all three resistant clones, 
and these were identified as primarily RNA helicases, in addition 
to copies of cysteine peptidase and several hypothetical proteins. 
As the data for the RNA helicases have different significance and 
expression values, it is unlikely that the identification of this gene 
family is due to multimapping as in the Histone H4 genes, in this 
case leading to a firmer conclusion that all individual genes identified 
are differentially expressed (Table S3, worksheet “RNAseq_UP”). In 
F I G U R E  1 0   Differential gene expression in three independent DA- resistant clones (4C2, 5C1 and 6C3) of T. congolense IL3000. For each 
DA- resistant clone, Log2 fold change was calculated compared with wild- type parasites, as well as significance (q- value), and plotted as a 
volcano plot. Differential gene expression was deemed significant if the gene exhibited a Log2 fold change of >1 or <−1 in all three clones, 
as well as a q- value of <.05 (- Log10q- value of 1.30103) (genes shown as asterisks). The most significantly upregulated (Helicase associated 
domain (HA2) putative: TcIL3000.A.H_000255300.1) and downregulated (Histone H4 putative: TcIL3000.A.H_000205600.1) genes are 
shown as circled asterisks to illustrate reproducibility across clones
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some cases, there was significant differential expression in only two 
of the DA- resistant clones, for example, a predicted long- chain fatty 
acid- CoA ligase (TcIL3000.A.H_00065500.1; mean q- value: .0356; 
mean Log2 fold change: −0.297).
3  | DISCUSSION
In this manuscript, we have studied the phenomenon of dimina-
zene resistance in T. congolense. This veterinary parasite does not 
have an equivalent of the T. brucei diminazene transporter TbAT1 
(Munday et al., 2013) and thus it is clear that the T. brucei model for 
diminazene resistance, based on loss of TbAT1 function (De Koning 
et al., 2004; Graf et al., 2013), is not applicable to T. congolense.
We found that it was possible to induce a substantial level of 
diminazene resistance in T. congolense by slowly increasing the drug 
concentration in the culture medium. The level of DA resistance was 
entirely stable in all clones, after months of in vitro passage in the 
absence of drug pressure, and repeated cycles of stabilating and re-
culturing. Remarkably, all the independently generated DA- resistant 
clones displayed the same level of resistance, cross- resistance pat-
terns, and growth rates, which could indicate that they had devel-
oped very similar adaptations.
One of the main aims of this study was to establish whether DA 
resistance in T. congolense necessarily leads to cross- resistance to 
other (potential) AAT drugs. Co- resistance with isometamidium chlo-
ride has been reported in the field (Afewerk et al., 2000; Ainanshe 
et al., 1992; Mulugeta et al., 1997), but it is not clear whether this 
constitutes genuine cross- resistance. This conclusion can be hard to 
reach in the field as cattle are often treated with both drugs and 
independently developed resistance to both drugs is therefore a real 
possibility.
However, there have been reports of single resistance to dimina-
zene and to isometamidium, and more recently to both drugs (Geerts 
et al., 2001; Giordani et al., 2016; Sinyangwe et al., 2004). This clearly 
shows that multiple- resistance is not automatic, as it seems to be for 
pentamidine and melarsoprol in T. brucei sspp. (Baker et al., 2013). 
Our observation that induced DA resistance in T. congolense did not 
change isometamidium sensitivity in any of the independent clones 
is certainly a strong confirmation of that hypothesis and to the best 
of our knowledge the first such evidence from a controlled labora-
tory study since experiments in 1963 by Frank Hawking with mul-
tiple T. congolense strains in guinea pigs and mice, which also found 
no evidence of cross- resistance between DA and phenanthridines 
(Hawking, 1963). We have also attempted to similarly induce isomet-
amidium resistance in T. congolense, but this was not successful in 
vitro although it has been achieved in vivo (Tihon et al., 2017). 
Another important observation on the nature of DA resistance in T. 
congolense is that it was remarkably stable, which, considering the 
many reports of DA resistance from all over Africa, has implications 
for the future utility of the drug.
As mentioned earlier, it has been argued that the further devel-
opment of diamidine drugs against AAT would be unwelcome and 
only result in more drug pressure on populations that already harbor 
DA resistance. The strong cross- resistance with furamidines such 
as DB75 and DB829, observed both in vitro and in vivo and with 
field isolates and in vitro- adapted clones, would certainly strengthen 
this argument. However, the complete lack of cross- resistance 
with pentamidine and the tested series of bis- benzofuramidines 
demonstrates that only the closest structural analogs display cross- 
resistance with DA, and that therefore not all diamidines should be 
ruled out from consideration for further development against AAT. 
The caveat, however, would be that any new diamidine drug must 
be active, at a minimum, against all the major species causing na-
gana in sub- Saharan Africa, including DA- resistant strains of each of 
those species. Given the dearth of knowledge about DA- resistant T. 
vivax, in particular, this would still constitute a significant hurdle at 
the moment. In this context, the observation that there is no cross- 
resistance between DA and oxaboroles, promising new agents in de-
velopment for HAT and AAT (Akama et al., 2018; Begolo et al., 2018; 
Jacobs et al., 2011), is highly significant.
In T. brucei, drug resistance is mostly linked to changes in drug 
accumulation, particularly through mutations in transporter genes 
(De Koning, 2020). In T. congolense, isometamidium resistance has 
also been linked to reduced accumulation (Mulugeta et al., 1997; 
Sutherland et al., 1991, 1992; Tihon et al., 2017), but no drug trans-
porters have been identified in this species. We therefore investi-
gated the uptake of [3H]- DA in wild- type IL3000 and found it to be 
very slow and, apparently, low affinity. This indicates that uptake of 
diminazene could be limiting to its efficacy, whereas in T. brucei sspp 
uptake of diminazene, the furamidines, and pentamidine is very fast 
with high affinity (De Koning et al., 2004; De Koning & Jarvis, 2001; 
Teka et al., 2011; Ward et al., 2011). We found no consistent indica-
tion that DA resistance in T. congolense is linked to reduced cellular 
accumulation of the drug, as the accumulation rate was similar in the 
parental and resistant clones.
Several compounds were identified as inhibitors of both [3H]- 
diminazene and fluorescent DB75 uptake in T. congolense, particu-
larly pentamidine, propamidine, and folate. The latter observation 
indicates the involvement of folate transporters in diminazene up-
take, although high concentrations were required for significant 
inhibition and even then diminazene uptake was only partially inhib-
ited. Clearly, a so- far unidentified, folate- insensitive uptake mech-
anism is additionally involved in diminazene uptake. The notion of 
multiple low- affinity entry routes was further strengthened by the 
demonstration that inhibition by folate and pentamidine was addi-
tive, and yet still incomplete. To further investigate whether T. con-
golense folate transporters may contribute to diminazene uptake, 
all three then- known FTs were cloned and expressed in the diami-
dine- and melaminophenyl- resistant clone T. brucei B48 (Bridges 
et al., 2007). The expression of IL3000 transporters FT1 and FT3 
appeared to induce a small but significant sensitization to dimina-
zene and its structural analog, DB829, but not to pentamidine or 
oxaborole AN7973; IL3000 FT2 trended in the same direction as 
the other two transporters, but the effect did not reach statistical 
significance. The folate transporters of two DA- resistant isolates 
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from Cameroon displayed several SNPs relative to the IL3000 se-
quences, but the levels of sensitization induced by those FTs were 
not significantly different from those of IL3000. However, FT2 from 
both resistant isolates significantly sensitized to all three diamidines 
including pentamidine, but FT2 from IL3000 did not sensitize to any 
of the diamidines tested. None of the FTs changed the EC50 value 
for AN7973. These observations show that the folate transporters 
have a minor capacity for diamidine transport, but also that SNPs 
observed in these genes are not the cause of DA resistance, either 
in the field or in our laboratory- adapted clones. The lack of genuine 
resistance mutations in the folate transporters is presumably linked 
to the observation that at least two of those transporters have this 
capacity, and that the FTs mediate only a proportion of DA uptake, 
considering the modest effect of 1 mM folate on [3H]- diminazene 
uptake.
Based on the above reasoning, we must conclude that dimi-
nazene resistance in T. congolense is not principally the result of a 
reduced rate of cellular diminazene accumulation. The alternative 
cause of resistance would be in changes of the target. In the case 
of diminazene and other cationic drugs this target is the mitochon-
drion (Alkhaldi et al., 2016; Basselin et al., 2002; Fueyo Gonzalez 
et al., 2017; Lanteri et al., 2008), and the fluorescent DB75 has been 
shown to accumulate in the kinetoplast (Mathis et al., 2006, 2007; 
Stewart et al., 2005), binding to the kDNA or interfering with en-
zymes involved in the functioning and/or replication of the kineto-
plast. We confirm the mitochondrial targeting of DA in T. congolense 
with TEM, showing mitochondrial lesions appearing after a 4- hr 
incubation with 1.5 µM DA (~5 × EC50), whereas no other cellular 
changes were apparent. While dyskinetoplastic T. brucei have been 
described, including as part of the adaptation to isometamidium (Eze 
et al., 2016), and T. evansi is considered a dyskinetoplastic T. brucei 
(Lun et al., 2010), dyskinetoplastic T. congolense have not been de-
scribed, and our DA- resistant clones displayed normal kinetoplasts 
as observed by DAPI staining and TEM. Thus, unlike T. brucei sspp 
(Dean et al., 2013; Eze et al., 2016), T. congolense does not appear 
to have the ability to become resistant to kinetoplast- targeting 
drugs by losing dependence on genes encoded by kDNA. T. brucei 
bloodstream forms have a unique mitochondrial function and lack 
the usual oxidative phosphorylation pathways, instead employing 
a trypanosome alternative oxidase (TAO) as the sole terminal oxi-
dase (Chaudhuri et al., 1998; Ebiloma et al., 2018, 2019) and using 
the F1Fo- ATPase to pump H
+ from the mitochondrial matrix and so 
generate the necessary Ψm (Schnaufer et al., 2005). Bloodstream 
T. congolense may have a similar energy metabolism and mitochon-
drion, seeing that they have similar sensitivity to inhibitors of TAO 
(Fueyo Gonzalez et al., 2017) and no sensitivity to cyanide (Bienen 
et al., 1991).
However, in order to reach and disable the kinetoplast and/or 
other mitochondrial targets, the drug must accumulate inside the 
mitochondrion— a process that is dependent on the mitochondrial 
membrane potential Ψm. We observed, in all four DA- resistant 
clones investigated, a statistically significant reduction in Ψm, 
which might serve to diminish the entry of diminazene into the 
mitochondrion, where the drug would otherwise be strongly ac-
cumulated. Although DA and structurally related diamidines bind 
to kDNA, it should be mentioned that the lesions observed with 
TEM were in the mitochondrial matrix rather than any observable 
alterations to the kinetoplast structure, leaving open the possi-
bility of mitochondrial targets other than the kinetoplast. This is 
particularly important as the entry of the drug into T. congolense is 
low affinity and inefficient, as opposed to the energy- dependent, 
high affinity process in T. brucei. Diminazene uptake in T. congo-
lense is thus very likely equilibrative rather than concentrative, 
implying that a failure of the drug to accumulate in the mitochon-
drion will eventually result in a reduced cellular uptake as well. A 
reduced (rate of) diminazene accumulation in the mitochondrion 
of the resistant cells would be consistent with the observed of 
lack of diminazene- induced mitochondrial lesions at 4 hr and rela-
tively few alterations even at 8 hr. However, we acknowledge that 
the reduced mitochondrial membrane potential is likely not the 
only, or main, factor contributing to DA resistance, particularly as 
we did not observe a reduced time- to- fluorescence for kDNA on 
incubation with DB75. Moreover, the lack of cross- resistance to 
pentamidine and isometamidium also indicates that a more spe-
cific adaptation is likely to be at least partly responsible for the 
narrow resistance phenotype. In light of these observations, it is 
likely that the reduced Ψm is the result of that adaptation, rather 
than the primary cause of the DA resistance.
Genomic and transcriptomic analyses of the 4C2, 5C1, and 6C3 
DA- resistant clones were performed to further investigate the 
causes of resistance. For each clonal line, several hundred genes 
were differentially regulated, relative to the parental clone IL3000. 
After filtering- out inconsistent and functionally irrelevant returns 
relatively few genes were significantly downregulated (including H4 
histones, a cathepsin- like cysteine protease, and several hypothet-
ical proteins with no known domains) or upregulated (mainly RNA 
helicases and a few hypothetical proteins). However, the highly sta-
ble level of resistance would be consistent with permanent muta-
tions rather than the more transient changes in transcription. The 
genomic sequencing revealed 19 high impact SNPs and 192 high 
impact indels. SNPs were observed in several transporter genes, 
including amino acid transporters, some of the folate transporter 
genes and a putative choline transporter, as well as mitochondrial 
HSP60, but mostly in only 1 of the resistant clones. Most interest-
ingly, however, in all three DA- resistant clones sequenced, missense 
mutations were observed in at least one of two copies of a vacuolar- 
type Ca2+- ATPase.
The mutations in the vacuolar Ca2+- ATPases could be relevant to 
a resistance mechanism that is linked to mitochondrial function, as 
trypanosome mitochondria are known stores of Ca2+ (Ramakrishnan 
& Docampo, 2018), which appears to be released to the cytosol upon 
membrane depolarization (Alkhaldi et al., 2016) though a Ca2+/H+ ex-
changer (Ramakrishnan & Docampo, 2018), and the bioenergetics of 
trypanosomes is regulated by inositol 1,4,5- trisphosphate receptor- 
mediated Ca2+- release from acidocalcisomes (Chiurillo et al., 2020; 
Huang, Bartlett, et al., 2013) and a mitochondrial Ca2+ uniporter 
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(Huang, Vercesi, et al., 2013). The T. congolense Ca2+- ATPases are syn-
tenic with T. brucei vacuolar Ca2+/H+ antiporters PMC1 and PMC2, 
which are essential genes and localized to the acidocalcisomes 
(Huang & Docampo, 2015; Luo et al., 2004). RNAi knockdown of 
TbPMC1 expression increased cytosolic calcium levels but reduced 
the amount of Ca2+ in intracellular stores. Interestingly, diamidines 
including DB75 and DB820 have been shown to accumulate not just 
in the nucleus and kinetoplast of T. brucei, but also in the acidocal-
cisomes, as evidenced by a slow- onset yellow- orange fluorescence 
(Mathis et al., 2006). Acidocalcisomes have been described as drug 
targets and have essential regulatory roles in trypanosomes, particu-
larly concerning ion distribution, pH, and Ca2+- signaling (Docampo & 
Moreno, 2008). As such, the two missense mutations in the vacuolar- 
type Ca2+- ATPase, each of which occurred in two independent clones, 
should certainly be followed up as potential contributing factors in T. 
congolense DA resistance, but this will clearly require extensive fur-
ther validation. The very high level of DA- induced SNPs and indels is 
consistent with the DNA- targeting nature of this minor grove binder.
Altogether, we conclude that a clinically relevant level of DA- 
resistance in T. congolense can be induced in vitro and is stable, and not 
primarily due to reduced DA accumulation but instead associated with a 
reduced mitochondrial membrane potential, although this is not likely to 
be the main cause of the resistance phenotype. DA uptake is low affin-
ity and partially mediated not only by the T. congolense folate transport-
ers, but also by separate transporters that are sensitive to pentamidine. 
These results constitute the first systematic analysis of DA- transport 
and resistance mechanisms in T. congolense and provide some insights 
important for the development of new drugs against AAT.
4  | E XPERIMENTAL PROCEDURES
4.1 | In vitro culture of T. congolense
Cultures of bloodstream forms of Savannah- type strain IL3000 and 
the adapted clones derived from this strain were cultured exactly as 
described by Coustou et al. (2010), in a basal MEM- based medium sup-
plemented with 20% goat serum 14 μl of β- mercaptoethanol, 800 μl of 
200 mM glutamine solution, and 10 ml of 100× penicillin/streptomy-
cin solution per liter of medium (pH = 7.3). T. congolense were cultured 
in 6- or 24- well plates at 34°C and 5% CO2. For adaptation to DA, cul-
tures were serially passaged in the highest concentration of DA toler-
ated, which was increased as the cells adapted, starting at 50 nM DA 
(Sigma). Thus one 24- well plate contained 1 row of “no drug” control 
culture of IL3000 bloodstream forms and three rows of independent 
cultures in the presence of DA, in three drug concentrations per pas-
sage, one above and one below the concentration under test.
4.2 | Resazurin assay with T. congolense
This drug susceptibility assay was performed essentially as de-
scribed previously (Cerone et al., 2019) and is based on only live 
cells reducing the blue and non- fluorescent viability indicator dye 
resazurin sodium salt (“Alamar blue”; Sigma) to pink, fluorescent 
metabolite resorufin (Gould et al., 2008). The fluorescence was 
quantified using a FLUOstar Optima (BMG Labtech, Durham, NC, 
USA) at wavelength of 540 nm (excitation), 590 nm (emission), and 
the data plotted to a sigmoidal curve with variable slope using Prism 
5.0 (GraphPad Software Inc., San Diego, CA, USA). The assay was 
set up in 96- well plates with the test drug added at doubling dilu-
tions in culture medium, usually starting at 50 µM, over one or two 
rows of the plate, with the last well receiving 100 µl culture medium 
as a drug- free control, that is either 11 or 23 doubling dilutions. To 
each well, 100 µl of culture medium containing 5 × 105 bloodstream 
T. congolense cells was added, and the plate was incubated for 48 hr 
at 34ºC/5% CO2, followed by the addition of 20 µl of a 125 mg/
ml solution of resazurin sodium salt in phosphate- buffered saline 
(PBS) and a further incubation period of 24 hr.
4.3 | In vivo experiments and ethics statement
Drug sensitivity testing in mice used the standardized single- dose 
procedure of Eisler et al. (2001). Groups of six NIH mice (Envigo) 
were used throughout, and infected i.p. with 105 T. congolense of 
strain IL3000 or KONT2/151 in phosphate- buffered saline pH 7.4 
(PBS). At 24 hr post infection (PI) a single dose of DB829, AN7973, 
or vehicle (DMSO, drug- free control) was administered i.p., at doses 
10, 20, or 40 mg/kg bw for DB829 and 5, 10, or 20 mg/kg bw for 
AN7973. Parasitemia was monitored daily, scored by microscopic 
analysis of blood from a tail prick from each infected animal. Any 
mouse found to have high parasitamia during the experiment, or 
show any signs of suffering were euthanized by CO2 inhalation. All 
animal experimentation was performed at the University of Glasgow 
Joint Research Facility under the supervision of trained profession-
als; the facility is regularly inspected by a UK Home Office Inspector 
and adheres to all national and international regulations as stipulated 
by the UK Home Office for animal care and in accordance with the 
Animals (Scientific Procedures) Act 1986 as amended in 2012. The 
procedure had been expressly approved and licensed by the UK 
Home Office (project license PCF371688), and the experiment was 
performed by a trained animal technician under his personal Home 
Office license (PIL601/12386).
4.4 | Fluorescence microscopy screen for diamidine 
uptake inhibitors
NIH mice (Envigo) were infected with 100,000 trypanosomes of ei-
ther T. b. brucei strain Lister 427 (i.p.), T. congolense strain IL3000 
(i.p.) or T. vivax strain Y486 (Gibson, 2012) (i.v.) in PBS; each parasite 
species was injected in sterile saline solution. At peak parasitemia, 
the mouse was killed by CO2 inhalation and the blood collected by 
aortic bleed. This was kept on ice if not being used immediately for 
an experiment.
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Approximately, 1 ml of whole blood was spun at 1,000 × g, and 
supernatant, buffy coat and a visible layer of parasites were removed 
to a new tube and spun again. The resulting pellet was washed with 
1 ml of CBSS buffer (25 mM HEPES, 120 mM NaCl, 5.4 mM KCl, 
0.55 mM CaCl2, 0.4 mM MgSO4, 5.6 mM Na2HPO4, 11.1 mM glu-
cose; pH adjusted to 7.4 with NaOH), and the pellet resuspended 
in CBSS buffer at an appropriate concentration to visualize the par-
asites (usually 1 ml). The duration of viability of parasites was as-
sessed at room temperature, 34ºC and 4ºC prior to completion of 
experiments. T. congolense parasites performed similarly when kept 
at 34ºC and room temperature during experiments; therefore, ex-
periments were conducted at room temperature; T. vivax parasites 
were motile for longer and took up DB75 at a faster rate at 34ºC, 
so were kept at this temperature as much as possible during experi-
ments (but not while under the microscope for observation).
For non- inhibited cells, 10 µM of DB75 was added and fluores-
cence observed using a Zeiss Axioscope fluorescence microscope, 
using the DAPI filter set (λexc = 330 nm, λem = 400 nm) as well as 
brightfield. Images were obtained with Openlab imaging software 
(Improvision, Coventry, UK). For inhibited cells, the test inhibitor 
was added to the desired concentration (see Table S1) just before 
the addition of 10 µM DB75 and observation of fluorescence as be-
fore. Each potential inhibitor was tested at least twice on parasites 
from different mice, those which inhibited up to four times. Every 
experiment had cells with no inhibitor added visualized in parallel to 
control for slight variation in timing of appearance of fluorescence in 
kinetoplasts and nuclei between batches of ex vivo parasites.
4.5 | Transport assays
Transport assays for T. congolense bloodstream forms were per-
formed exactly as described for T. b. brucei bloodstream forms 
(Wallace et al., 2002) and Leishmania major promastigotes (Al- Salabi 
et al., 2003). Depending on the assay, parasites were either purified 
from infected blood using a DEAE- cellulose column and a 6:4 ratio 
PSG buffer as described (Lanham & Godfrey, 1970), or collected from 
culture. Briefly, cells were washed into assay buffer (33 mM HEPES, 
98 mM NaCl, 4.6 mM KCl, 0.55 mM CaCl2, 0.07 mM MgSO4, 5.8 mM 
NaH2PO4, 0.3 mM MgCl2, 23 mM NaHCO3, 14 mM glucose, pH 7.3) 
and adjusted to a density of 108/ml just before use. About,100 µl of 
the cell suspension was added to 100 µl of radiolabeled substrate (3H- 
DA or 3H- pentamidine) in assay buffer, sometimes also containing a 
competitive inhibitor at 2× final concentration, atop a layer of oil (1:7 of 
mineral oil and di- n- butyl phthalate (Sigma)) in a 1.5 ml microfuge tube. 
After a predetermined incubation time, the incubation was stopped 
by the addition of 1 ml ice- cold “stop solution” (1 mM/250 µM unla-
beled permeant in assay buffer), and cells were separated from the 
extracellular radiolabel by centrifugation through the oil layer (1 min at 
13,000 rpm in a microfuge). The cell pellets were harvested into scin-
tillation tubes by cutting off the tip of the microfuge tube after flash- 
freezing in liquid nitrogen, incubated with 2% SDS for at least 1 hr, and 
overnight with scintillation fluid (Optiphase HiSafe III, Perkin- Elmer, 
Waltham, MA, USA) before being agitated overnight in scintillation 
fluid (Optiphase HiSafe III, Perkin- Elmer, Waltham, MA, USA). Tubes 
were then read using a Hidex 300 SL scintillation counter (Lablogic, 
Sheffield, UK). Raw disintegrations per minute (dpm) reads were con-
verted to units of pmol(107 cells)- 1 and corrected for background radia-
tion and non- specific radiolabel association, by subtracting dpm counts 
from no- label controls and parallel determinations in the presence of 
saturating levels of non- labeled permeant, respectively. Radiolabeled 
ring- [3H]- DA was custom- made by PerkinElmer (CUST78468000MC; 
60.7 Ci/mmol) and [3H]- pentamidine isethionate was custom- made by 
Amersham (TRQ40084; 3.26 TBq/mmol). [3,5,7,9- 3H]- folic acid (ART 
0125; 56.8 Ci/mmol) was from American Radiolabeled Chemicals. 
Statistical analyses were performed with GraphPad Prism 8.1.
4.6 | Cloning and expression of T. congolense folate 
transporters
Three folate transporters were identified in the original T. congolense 
IL3000 genome available in TriTrypDB (version 1 of the genome, re-
leased Oct 20 2010). The gene designated as Folate Transporter (FT) 
1 (TcIL3000.10.7850) was annotated as a predicted pteridine trans-
porter, and FT2 (TcIL3000.0.06950) and FT3 (TcIL3000.0.13340) 
were predicted folate transporters.
Subsequent to the completion of the cloning work described 
in this paper, the T. congolense IL3000 2019 genome was re-
leased in TriTrypDB (release Nov 6 2019); this contains several 
(additional) predicted genes all annotated as putative folate 
transporters. TcIL3000.A.H_000799700 aligns with our FT1 
(GenBank accession numbers in Table 2 and Fig. S2). Three tan-
demly arranged, almost identical genes (97.8%– 98.4% identity), 
TcIL3000.A.H_000597400, TcIL3000.A.H_000597500, and 
TcIL3000.A.H_000597700, align with our FT2 with 97.3%– 99.8% 
identity by Clustal Omega analysis. And two genes annotated as 
being pseudogenes due to missing START and STOP codons, Tc
IL3000.A.H_000531600:pseudogene and TcIL3000.A.H_000
558900:pseudogene, align with our FT3. The predicted CDS of 
TcIL3000.A.H_000531600 is the same as the IL3000 FT3, only 
having a predicted N- terminal extension with no START codon. 
The last 27 amino acids and STOP codon that are missing from 
the sequence given on the TriTrypDB gene page are actually pres-
ent when the full contig is examined. There are long stretches of 
TcIL3000.A.H_000558900 that are divergent (67.9% identical by 
Clustal Omega analysis). All are aligned in Figure S2.
Based on the TritrypDB sequences obtained, primers were de-
signed to amplify the three genes with either an ApaI or HindIII 5′ 
restriction site and a 3′ XbaI restriction site. The Primer sequences 
were as follows: FT1_F 5′- gggcccATGTTTGGCACGGCTGCG- 3′; 
FT1_R 5′- tctagaCTATCTGCGGGCCTCA- 3′; FT2_F 5′- aagcttATGAG 
CGCACCAACCGAC- 3′; FT2_R 5′- tctagaCTACCTTACTTCATTGTC
TG- 3′; FT3_F 5′- gggcccATGTTTGGCGAAGCAACTG- 3′ and FT3_R 
5′- tctagaCTACCTTACTTCATTGTCTG- 3′. Genomic DNA was ex-
tracted from parasites isolated from 1 ml of cardiac puncture blood 
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from mice infected with each strain: IL3000, KONT2/133, and 
KONT2/151, using a Qiagen DNeasy blood and tissue kit, following 
the manufacturer's instructions. Genes were amplified from the rel-
evant gDNA using the primers given above and Phusion polymerase 
(New England Biolabs), following the manufacturer's protocol. DNA 
fragments of approximately the correct size were extracted from 
1% agarose gels and ligated into the pGEMT- Easy (Promega) sub-
cloning vector. Positive colonies were identified by screening using 
the M13F/M13R sequencing primers on the vector and sequenced 
by Sanger sequencing (Source BioScience, Nottingham UK). The 
identified sequences were ligated into the vector pHD1336 and 
transfected into T. b. brucei strain B48 (Bridges et al., 2007) using an 
Amaxa Nucleofector, program X- 01, and TbBSF buffer as described 
previously (Burkard et al., 2007; Munday et al., 2013). Transfectants 
were cloned out, by limiting dilution, in standard HMI- 11 medium 
(Hirumi & Hirumi, 1989) containing 5 µg/ml blasticidin S and clones 
screened for correct integration of the cassette by PCR. All clones 
were maintained in HMI- 11 using standard growth conditions, 37ºC 
and 5% CO2.
Drug sensitivity of the T. brucei cell lines was assessed using the 
standard resazurin assay, essentially as described for T. congolense, 
above and as described previously (Siheri et al., 2016). Briefly, the 
assay was performed in 96- well plates with 11 doubling test com-
pounds dilutions, highest concentration 10 µM, and the 12th well 
containing cells in drug- free medium. Bloodstream form of 2 × 104 
trypanosomes were added to each well, and the plates were incu-
bated for 48 hr at 37°C/5% CO2 after which 20 µl of resazurin solu-
tion was added to each well and the plates incubated for another 
24 hr.
4.7 | Mitochondrial membrane potential (Ψm) assay
Changes in Ψm were determined by flow cytometry using the indi-
cator dye tetramethylrhodamine ethyl ester (TMRE) as the probe, 
exactly as previously described (Cerone et al., 2019; Ibrahim 
et al., 2011). Briefly, bloodstream forms of 1 × 107 T. congolense 
IL3000 and several IL3000- adapted DA- Res clonal lines in mid- log 
growth phase were centrifuged at 1,600 × g for 10 min at 4°C and 
washed in 1 ml pf PBS (pH 7.4) and finally resuspended in 1 ml PBS 
containing 200 nM TMRE. These cells were incubated for 30 min 
at room temperature and then placed on ice for a further 30 min 
prior to analysis on a Becton Dickinson FACSCalibur™ system (BD 
Biosciences) using a FL2- height detector, and CellQuest and FlowJo 
10 software.
4.8 | DAPI staining of nuclei and kinetoplasts
Approximately, 1 × 106 cells were harvested in Eppendorf tube 
and centrifuged at 2,400 rpm for 10 min in a microfuge. The super-
natant was discarded; the cells were resuspended in 1× PBS and 
washed by centrifugation (2,400 rpm for 5 min). The supernatant 
was discarded; the cells were resuspended in 50 µl 1× PBS pH 7.4, 
spread out on a microscope slide and allowed to dry for 30 min. 
The cells were then fixed by flooding the slide with 4% formal-
dehyde for 10 min, followed by washing twice in 1× PBS. The 
slides were allowed to air dry before placing a drop of Vectashield 
mounting medium containing DAPI (4′,6- diamidino- 2- phenylindole 
dihydrochloride) (Vector Laboratories) on them. The slides were 
then covered with a cover slip and the edges sealed with nail var-
nish. The slides were viewed under a DeltaVision microscope (GE 
Healthcare) using softWoRx software and the images were pro-
cessed using ImageJ software.
4.9 | Transmission electron microscopy
T. congolense WT and diminazene- resistant clone 6C3 were pre-
pared essentially as described previously for T. b. brucei (Cerone 
et al., 2019; Millán et al., 2017) at about 1 × 106 cells/ml with or 
without diminazene at 1.5 µM in TCBSF3 medium. The samples were 
incubated at 34ºC and 5% CO2 for 4 or 8 hr, centrifuged at 1,100 × g 
for 10 min and washed in 1× PBS. The pellets were resuspended 
and fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2) 
overnight at 4ºC, then washed in 0.1 M cacodylate buffer (pH 7.2), 
and post- fixed in 1% OsO4 for 1 hr on ice. After several washes in 
the same buffer, the samples were en bloc stained with 0.5% ura-
nyl acetate in water for 30 min. Thereafter, samples were washed 
with water, dehydrated in an ascending acetone series, and embed-
ded in epoxy resin. Ultrathin sections were collected and imaged on 
a JEOL 1200 Transmission electron microscope (JEOL, Japan). All 
images obtained were analyzed and processed with FIJI software 
(Schindelin et al., 2012).
4.10 | RNAseq
Total RNA isolations were performed on 1 × 107 cells of a paren-
tal strain of wild- type T. congolense IL3000, as well as three repli-
cates of each of the three independent DA- resistant clones (4C2, 
5C1 and 6C3), using a commercial kit (RNeasy, QIAgen). Samples 
were enriched for mRNA by Poly- A selection, using the TruSeq 
stranded mRNA sample preparation kit (Illumina, catalog number 
20020594) and subsequently quantified using Qubit high sensitiv-
ity reagents (Thermo). Average library size was determined using 
DNA high- sensitivity reagents for the Agilent bioanalyser 2100 
(Agilent). For sequencing, 2 × 75 bp paired- end sequencing was 
carried out using an Illumina NextSeq 500 system (Illumina), re-
sulting in an average of 12 million reads per sample. For RNA- seq 
data processing, reads contained in the resultant fastq files were 
aligned to the PacBio genome of the T. congolense strain IL3000 
(Abbas et al., 2018) and gene abundances quantified, in both 
cases using Kallisto with default parameters (−b 100, −t 8) (Bray 
et al., 2016). Statistical analyses of differential expression between 
the wild- type parental strain and each of the three resistant clones 
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were carried out using the R- based package Sleuth, with default 
parameters (for each transcript, a second fit was performed to a 
reduced model that presumes abundances are equal in the two 
conditions— wild- type and DA- resistant) as outlined in the manual 
(Bray et al., 2016), and figures were generated with Matlab (The 
MathWorks, Inc.). Genes exhibiting significant (q- value ≤.05) dif-
ferential expression between wild- type and resistant parasites 
were tabulated and filtered to remove VSGs, ESAGs and retro-
transposon hot spot proteins, and subsequently sorted to obtain 
genes with significance based on q- value (i.e., p- value adjusted for 
multiple testing by false discovery rate). The full Sleuth output is 
available in Table S3, worksheet “RNAseq_all”.
4.11 | Whole- genome analysis
For whole- genome analysis, DNA was extracted from in vitro cul-
tures (3 × 106 cells) of the T. congolense IL3000 wild type line, as 
well as the three DA- resistant lines (4C2, 5C1, and 6C3), using the 
QIAgen DNeasy kit. Libraries were prepared using the QIAseq FX 
DNA library kit (QIAgen, cat: 180475). The libraries were quanti-
fied using Qubit high sensitivity reagents (Thermo), and average li-
brary size was determined using DNA high sensitivity reagents for 
the Agilent bioanalyser 2100. The four samples were subsequently 
paired- end (2 × 75 bp) sequenced using Illumina NextSeq500 to 
an average of 15 million reads per sample. SNP and indel analysis 
were carried out on the resulting data using the GATK pipeline 
(McKenna et al., 2010). Reads were first trimmed using cutadapt 
(parameters: −q 30, 30 −minimum- length = 70 −pair- filter = any) 
(Martin, 2011) and subsequently aligned to the PacBio T. con-
golense IL3000 assembly (Abbas et al., 2018) using STAR (pa-
rameters: −outSAMtype BAM unsorted −readNameSeparator_ 
−readFilesCommand zcat −runThreadN 8) (Dobin et al., 2013). The 
resulting bam files were further processed with Picard (functions: 
AddOrReplaceGroups & MarkDuplicates) (Mckenna et al., 2010) 
and GATK (functions: SplitNCigarReads, HaplotypeCaller, 
VariantFiltration, SelectVariants) to generate separate files for 
SNPs and indels. Further filtering was carried out on these files 
using the SnpEff tool (parameter: SnpSift.jar filter “(FILTER = 
‘PASS’)”) (Cingolani, Platts, et al., 2012). Final datasets for SNPs 
and indels were created using the SnpEff command (SnpEff.jar), 
and data were extracted into tabular form using the SnpSift com-
mand (Cingolani, Patel, et al., 2012) (extractFields— CHROM POS 
ID REF ALT FILTER “ANN[*].GENE” “ANN[*].GENEID” “ANN[*].
FEATURE” “ANN[*].EFFECT” “ANN[*].IMPACT” “ANN[*].CODON” 
“ANN[*].AA” “ANN[*].ALLELE” “GEN[*].GT”). The resulting data 
were filtered firstly to remove SNPs occurring in both wild- type 
and resistant lines, and subsequently to select for SNPs and indels 
predicted to have a high (a variant that is assumed to result in a 
highly disruptive impact on the protein such as truncation or loss 
of function), moderate (non- disruptive variant that is assumed to 
impact protein effectiveness such as non- synonymous SNPs or in 
frame deletions) or low (Mostly harmless variants such as synony-
mous SNPs) impact, in both cases using Microsoft Excel.
ACKNOWLEDG MENTS
The Global Alliance for Livestock Veterinary Medicines (GALVmed) is 
gratefully acknowledged for funding this study. We thank professor 
Dave Boykin (Georgia State University, Atlanta, GA, US) and professor 
Richard Tidwell (University of North Carolina at Chapel Hill, Chapel 
Hill, NC, USA) contributed diamidine compounds, Professor Jan Van 
den Abbeele for the T. congolense KONT2/133 and KONT2/151 iso-
lates, and Pfizer, Anacor, and the Bill and Melinda Gates Foundation 
for the donation of oxaborole compounds. Mr. Craig Lapsley is grate-
fully acknowledged for making the sequencing libraries.
CONFLIC T OF INTERE S T
The authors declare that they have no conflict of interest regarding 
the publication of this research.
AUTHOR CONTRIBUTIONS
Tim G. Rowan, Liam J. Morrison, Michael P. Barrett, Rose Peter, 
Harry P. De Koning performed conception or design of the study. 
Lauren V. Carruthers, Jane C. Munday, Godwin U. Ebiloma, Pieter 
Steketee, Siddharth Jayaraman, Gustavo D. Campagnaro, Marzuq 
A. Ungogo, Leandro Lemgruber, Anne- Marie Donachie performed 
acquisition, analysis or interpretation of the data. Liam J. Morrison, 
Harry P. De Koning wrote the manuscript.
DATA AVAIL ABILIT Y S TATEMENT
Sequence data have been deposited in the European Nucleotide 
Archive (accession number PRJEB39051). All new sequence informa-
tion on cloned folate transporters was deposited with GenBank and 
accession numbers are included in the manuscript text (Table 2). All 
other relevant data are included in the manuscript or its Supporting 
Information.
ORCID
Gustavo D. Campagnaro  https://orcid.
org/0000-0001-6542-0485 
Harry P. De Koning  https://orcid.org/0000-0002-9963-1827 
R E FE R E N C E S
Abbas, A.H., Silva Pereira, S., D'Archivio, S., Wickstead, B., Morrison, L.J., 
Hall, N. et al. (2018) The structure of a conserved telomeric region as-
sociated with variant antigen loci in the blood parasite Trypanosoma 
congolense. Genome Biology and Evolution, 10, 2458– 2473. https://
doi.org/10.1093/gbe/evy186
Afewerk, Y., Clausen, P.- H., Abebe, G., Tilahun, G. & Mehlitz, D. (2000) 
Multiple- drug resistant Trypanosoma congolense populations in vil-
lage cattle of Metekel district, north- west Ethiopia. Acta Tropica, 76, 
231– 238. https://doi.org/10.1016/s0001 - 706x(00)00108 - x
Ainanshe, O., Jennings, F. & Holmes, P. (1992) Isolation of drug- resistant 
strains of Trypanosoma congolense from the Lower Shabelle Region of 
southern Somalia. Tropical Animal Health and Production, 24, 65– 73. 
https://doi.org/10.1007/bf023 56946
22  |     CARRUTHERS ET Al.
Akama, T., Zhang, Y.- K., Freund, Y.R., Berry, P., Lee, J., Easom, E.E. et al. 
(2018) Identification of a 4- fluorobenzyl l- valinate amide benzox-
aborole (AN11736) as a potential development candidate for the 
treatment of Animal African Trypanosomiasis (AAT). Bioorganic & 
Medicinal Chemistry Letters, 28, 6– 10. https://doi.org/10.1016/j.
bmcl.2017.11.028
Alghamdi, A.H., Munday, J.C., Campagnaro, G.D., Gurvic, D., Svensson, 
F., Okpara, C.E. et al. (2020) Positively selected modifications in the 
pore of TbAQP2 allow pentamidine to enter Trypanosoma brucei. 
eLife, 9, e56416. https://doi.org/10.7554/eLife.56416
Alkhaldi, A.A., Martinek, J., Panicucci, B., Dardonville, C., Zíková, A. & 
De Koning, H.P. (2016) Trypanocidal action of bisphosphonium salts 
through a mitochondrial target in bloodstream form Trypanosoma 
brucei. International Journal for Parasitology: Drugs and Drug 
Resistance, 6, 23– 34. https://doi.org/10.1016/j.ijpddr.2015.12.002
Al- Salabi, M.I., Wallace, L.J. & De Koning, H.P. (2003) A Leishmania major 
nucleobase transporter responsible for allopurinol uptake is a func-
tional homolog of the Trypanosoma brucei H2 transporter. Molecular 
Pharmacology, 63, 814– 820. https://doi.org/10.1124/mol.63.4.814
Alsford, S., Eckert, S., Baker, N., Glover, L., Sanchez- Flores, A., Leung, 
K.F. et al. (2012) High- throughput decoding of antitrypanosomal 
drug efficacy and resistance. Nature, 482, 232– 236. https://doi.
org/10.1038/natur e10771
Baker, N., De Koning, H.P., Mäser, P. & Horn, D. (2013) Drug resis-
tance in African trypanosomiasis: the melarsoprol and pentamidine 
story. Trends in Parasitology, 29, 110– 118. https://doi.org/10.1016/j.
pt.2012.12.005
Baker, N., Glover, L., Munday, J.C., Aguinaga Andres, D., Barrett, M.P., 
De Koning, H.P. et al. (2012) Aquaglyceroporin 2 controls suscep-
tibility to melarsoprol and pentamidine in African trypanosomes. 
Proceedings of the National Academy of Sciences, 109, 10996– 11001. 
https://doi.org/10.1073/pnas.12028 85109
Bakunova, S.M., Bakunov, S.A., Wenzler, T., Barszcz, T., Werbovetz, K.A., 
Brun, R. et al. (2007) Synthesis and in vitro antiprotozoal activity 
of bisbenzofuran cations. Journal of Medicinal Chemistry, 50, 5807– 
5823. https://doi.org/10.1021/jm070 8634
Basselin, M., Denise, H., Coombs, G.H. & Barrett, M.P. (2002) 
Resistance to pentamidine in Leishmania mexicana involves ex-
clusion of the drug from the mitochondrion. Antimicrobial Agents 
and Chemotherapy, 46, 3731– 3738. https://doi.org/10.1128/
aac.46.12.3731- 3738.2002
Basselin, M., Lawrence, F. & Robert- Gero, M. (1996) Pentamidine uptake 
in Leishmania donovani and Leishmania amazonensis promastigotes 
and axenic amastigotes. Biochemical Journal, 315, 631– 634. https://
doi.org/10.1042/bj315 0631
Begolo, D., Vincent, I.M., Giordani, F., Pöhner, I., Witty, M.J., Rowan, T.G. 
et al. (2018) The trypanocidal benzoxaborole AN7973 inhibits try-
panosome mRNA processing. PLOS Pathogens, 14, e1007315. https://
doi.org/10.1371/journ al.ppat.1007315
Bienen, E.J., Webster, P. & Fish, W.R. (1991) Trypanosoma (Nannomonas) 
congolense: changes in respiratory metabolism during the life 
cycle. Experimental Parasitology, 73, 403– 412. https://doi.
org/10.1016/0014- 4894(91)90064 - 4
Bray, N.L., Pimentel, H., Melsted, P. & Pachter, L. (2016) Near- optimal 
probabilistic RNA- seq quantification. Nature Biotechnology, 34, 525– 
527. https://doi.org/10.1038/nbt.3519
Bridges, D.J., Gould, M.K., Nerima, B., Mäser, P., Burchmore, R.J. & 
De Koning, H.P. (2007) Loss of the high- affinity pentamidine 
transporter is responsible for high levels of cross- resistance be-
tween arsenical and diamidine drugs in African trypanosomes. 
Molecular Pharmacology, 71, 1098– 1108. https://doi.org/10.1124/
mol.106.031351
Burkard, G., Fragoso, C. & Roditi, I. (2007) Highly efficient stable trans-
formation of bloodstream forms of Trypanosoma brucei. Molecular and 
Biochemical Parasitology, 153, 220– 223. https://doi.org/10.1016/j.
molbi opara.2007.02.008
Carter, N.S. & Fairlamb, A.H. (1993) Arsenical- resistant trypanosomes 
lack an unusual adenosine transporter. Nature, 361, 173– 176. https://
doi.org/10.1038/361173a0
Cerone, M., Uliassi, E., Prati, F., Ebiloma, G.U., Lemgruber, L., Bergamini, 
C. et al. (2019) Discovery of sustainable drugs for neglected tropi-
cal diseases: Cashew Nut Shell Liquid (CNSL)- based hybrids target 
mitochondrial function and ATP production in Trypanosoma brucei. 
ChemMedChem, 14, 621– 635. https://doi.org/10.1002/cmdc.20180 
0790
Chaudhuri, M., Ajayi, W. & Hill, G.C. (1998) Biochemical and molecular 
properties of the Trypanosoma brucei alternative oxidase. Molecular 
and Biochemical Parasitology, 95, 53– 68. https://doi.org/10.1016/
S0166 - 6851(98)00091 - 7
Chiurillo, M.A., Lander, E.S., Vercesi, A.E. & Docampo, R. (2020) IP3 
receptor- mediated Ca2+ release from acidocalcisomes regulates mi-
tochondrial bioenergetics and prevents autophagy in Trypanosoma 
cruzi. Cell Calcium, 92, 102284. https://doi.org/10.1016/j.
ceca.2020.102284
Cingolani, P., Patel, V.M., Coon, M., Nguyen, T., Land, S.J., Ruden, D.M. 
et al. (2012) Using Drosophila melanogaster as a model for genotoxic 
chemical mutational studies with a new program, SnpSift. Frontiers in 
Genetics, 3, 35. https://doi.org/10.3389/fgene.2012.00035
Cingolani, P., Platts, A., Wang, L.L., Coon, M., Nguyen, T., Wang, L. et al. 
(2012) A program for annotating and predicting the effects of single 
nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila 
melanogaster strain w1118; iso- 2; iso- 3. Fly, 6, 80– 92. https://doi.
org/10.4161/fly.19695
Coustou, V., Guegan, F., Plazolles, N. & Baltz, T. (2010) Complete in vitro 
life cycle of Trypanosoma congolense: development of genetic tools. 
PLoS Neglected Tropical Diseases, 4, e618. https://doi.org/10.1371/
journ al.pntd.0000618
De Koning, H.P. (2020) The drugs of sleeping sickness: their mecha-
nisms of action and resistance, and a brief history. Tropical Medicine 
and Infectious Disease, 5, 14. https://doi.org/10.3390/tropi calme 
d5010014
De Koning, H.P., Anderson, L.F., Stewart, M., Burchmore, R.J., Wallace, 
L.J. & Barrett, M.P. (2004) The trypanocide diminazene aceturate is 
accumulated predominantly through the TbAT1 purine transporter: 
additional insights on diamidine resistance in African trypanosomes. 
Antimicrobial Agents and Chemotherapy, 48, 1515– 1519. https://doi.
org/10.1128/aac.48.5.1515- 1519.2004
De Koning, H.P. & Jarvis, S.M. (1999) Adenosine transporters in blood-
stream forms of Trypanosoma brucei brucei: substrate recognition 
motifs and affinity for trypanocidal drugs. Molecular Pharmacology, 
56, 1162– 1170. https://doi.org/10.1124/mol.56.6.1162
De Koning, H.P. & Jarvis, S.M. (2001) Uptake of pentamidine in 
Trypanosoma brucei brucei is mediated by the P2 adenosine trans-
porter and at least one novel, unrelated transporter. Acta Tropica, 80, 
245– 250. https://doi.org/10.1124/mol.59.3.586
Dean, S., Gould, M.K., Dewar, C.E. & Schnaufer, A.C. (2013) Single point 
mutations in ATP synthase compensate for mitochondrial genome 
loss in trypanosomes. Proceedings of the National Academy of Sciences, 
110, 14741– 14746. https://doi.org/10.1073/pnas.13054 04110
Delespaux, V., Chitanga, S., Geysen, D., Goethals, A., Van den Bossche, 
P. & Geerts, S. (2006) SSCP analysis of the P2 purine transporter 
TcoAT1 gene of Trypanosoma congolense leads to a simple PCR- 
RFLP test allowing the rapid identification of diminazene resistant 
stocks. Acta Tropica, 100, 96– 102. https://doi.org/10.1016/j.actat 
ropica.2006.10.001
Delespaux, V. & De Koning, H.P. (2013) Transporters in antiparasitic 
drug development and resistance. In: Jäger, T., Koch, O. & Flohe, 
L. (Eds.) Trypanosomatid diseases: molecular routes to drug discovery. 
     |  23CARRUTHERS ET Al.
Wiley- Blackwell, pp 335– 349. https://doi.org/10.1002/97835 27670 
383.ch18
Díaz, M.V., Miranda, M.R., Campos- Estrada, C., Reigada, C., Maya, J.D., 
Pereira, C.A. et al. (2014) Pentamidine exerts in vitro and in vivo anti 
Trypanosoma cruzi activity and inhibits the polyamine transport in 
Trypanosoma cruzi. Acta Tropica, 134, 1– 9. https://doi.org/10.1016/j.
actat ropica.2014.02.012
Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S. et al. 
(2013) STAR: ultrafast universal RNA- seq aligner. Bioinformatics, 29, 
15– 21. https://doi.org/10.1093/bioin forma tics/bts635
Docampo, R. & Moreno, S.N.J. (2008) The acidocalcisome as a tar-
get for chemotherapeutic agents in protozoan parasites. Current 
Pharmaceutical Design, 14, 882– 888.
Ebiloma, G.U., Ayuga, T.D., Balogun, E.O., Gil, L.A., Donachie, A., Kaiser, 
M. et al. (2018) Inhibition of trypanosome alternative oxidase without 
its N- terminal mitochondrial targeting signal (ΔMTS- TAO) by cationic 
and non- cationic 4- hydroxybenzoate and 4- alkoxybenzaldehyde de-
rivatives active against T. brucei and T. congolense. European Journal 
of Medicinal Chemistry, 150, 385– 402. https://doi.org/10.1016/j.
ejmech.2018.02.075
Ebiloma, G.U., Balogun, E.O., Cueto Díaz, E.J., De Koning, H.P. & 
Dardonville, C. (2019) Alternative Oxidase inhibitors: development 
and efficient mitochondrion- targeting as a strategy for new drugs 
against pathogenic parasites and fungi. Medicinal Research Reviews, 
39, 1553– 1602.
Eisler, M.C., Brandt, J., Bauer, B., Clausen, P.- H., Delespaux, V., Holmes, 
P.H. et al. (2001) Standardised tests in mice and cattle for the de-
tection of drug resistance in tsetse- transmitted trypanosomes of 
African domestic cattle. Veterinary Parasitology, 97, 171– 183. https://
doi.org/10.1016/s0304 - 4017(01)00415 - 0
El- Gebali, S., Mistry, J., Bateman, A., Eddy, S.R., Luciani, A., Potter, S.C. 
et al. (2019) The Pfam protein families database in 2019. Nucleic Acids 
Research, 47, D427– D432. https://doi.org/10.1093/nar/gky995
Eze, A.A., Gould, M.K., Munday, J.C., Tagoe, D.N.A., Stelmanis, V., 
Schnaufer, A. et al. (2016) Reduced mitochondrial membrane poten-
tial Is a late adaptation of Trypanosoma brucei brucei to isometamid-
ium preceded by mutations in the γ subunit of the F1Fo- ATPase. PLoS 
Neglected Tropical Diseases, 10, e0004791. https://doi.org/10.1371/
journ al.pntd.0004791
Fueyo Gonzalez, F.J., Ebiloma, G.U., Izquierdo Garcia, C., Bruggeman, V., 
Sanchez Villamanan, J.M., Donachie, A. et al. (2017) Conjugates of 2, 
4- dihydroxybenzoate and salicylhydroxamate and lipocations display 
potent antiparasite effects by efficiently targeting the Trypanosoma 
brucei and Trypanosoma congolense mitochondrion. Journal of 
Medicinal Chemistry, 60, 1509– 1522. https://doi.org/10.1021/acs.
jmedc hem.6b01740
Geerts, S., Holmes, P.H., Eisler, M.C. & Diall, O. (2001) African bovine try-
panosomiasis: the problem of drug resistance. Trends in Parasitology, 
17, 25– 28. https://doi.org/10.1016/s1471 - 4922(00)01827 - 4
Gibson, W. (2012) The origins of the trypanosome genome strains 
Trypanosoma brucei brucei TREU 927, T. b. gambiense DAL 972, T. vivax 
Y486 and T. congolense IL3000. Parasites & Vectors, 5, 71. https://doi.
org/10.1186/1756- 3305- 5- 71
Giordani, F., Morrison, L.J., Rowan, T.G., De Koning, H.P. & Barrett, M.P. 
(2016) The animal trypanosomiases and their chemotherapy: a re-
view. Parasitology, 143, 1862– 1889. https://doi.org/10.1017/s0031 
18201 6001268
Gould, M.K., Vu, X.L., Seebeck, T. & De Koning, H.P. (2008) Propidium 
iodide- based methods for monitoring drug action in the kinetoplasti-
dae: comparison with the Alamar Blue assay. Analytical Biochemistry, 
382, 87– 93. https://doi.org/10.1016/j.ab.2008.07.036
Graf, F.E., Ludin, P., Wenzler, T., Kaiser, M., Brun, R., Pyana, P.P. et al. 
(2013) Aquaporin 2 mutations in Trypanosoma brucei gambiense field 
isolates correlate with decreased susceptibility to pentamidine and 
melarsoprol. PLoS Neglected Tropical Diseases, 7, e2475. https://doi.
org/10.1371/journ al.pntd.0002475
Hasne, M.- P. & Ullman, B. (2005) Identification and characterization 
of a polyamine permease from the protozoan parasite Leishmania 
major. Journal of Biological Chemistry, 280, 15188– 15194. https://doi.
org/10.1074/jbc.m4113 31200
Hawking, F. (1963) Drug- resistance of Trypanosoma congolense and other 
trypanosomes to quinapyramine, phenanthridines, Berenil and other 
compounds in mice. Annals of Tropical Medicine & Parasitology, 57, 
262– 282. https://doi.org/10.1080/00034 983.1963.11686181
Hirumi, H. & Hirumi, K. (1989) Continuous cultivation of Trypanosoma bru-
cei blood stream forms in a medium containing a low concentration 
of serum protein without feeder cell layers. Journal of Parasitology, 75, 
985– 989. https://doi.org/10.2307/3282883
Huang, G., Bartlett, P.J., Thomas, A.P., Moreno, S.N. & Docampo, R. 
(2013) Acidocalcisomes of Trypanosoma brucei have an inositol 
1,4,5- trisphosphate receptor that is required for growth and infectiv-
ity. Proceedings of the National Academy of Sciences, 110, 1887– 1892. 
https://doi.org/10.1073/pnas.12169 55110
Huang, G. & Docampo, R. (2015) Proteomic analysis of acidocalcisomes 
of Trypanosoma brucei uncovers their role in phosphate metabo-
lism, cation homeostasis, and calcium signalling. Communicative & 
Integrative Biology, 8, e1017174.
Huang, G., Vercesi, A.E. & Docampo, R. (2013) Essential regulation of cell 
bioenergetics in Trypanosoma brucei by the mitochondrial calcium 
uniporter. Nature Communications, 4, 2865. https://doi.org/10.1038/
ncomm s3865
Hunter, S., Apweiler, R., Attwood, T.K., Bairoch, A., Bateman, A., Binns, 
D. et al. (2009) InterPro: the integrative protein signature database. 
Nucleic Acids Research, 37, D211– D215. https://doi.org/10.1093/nar/
gkn785
Ibrahim, H.M.S., Al- Salabi, M.I., El Sabbagh, N., Quashie, N.B., Alkhaldi, 
A.A.M., Escale, R. et al. (2011) Symmetrical choline- derived dications 
display strong anti- kinetoplastid activity. Journal of Antimicrobial 
Chemotherapy, 66, 111– 125. https://doi.org/10.1093/jac/dkq401
Jacobs, R.T., Nare, B., Wring, S.A., Orr, M.D., Chen, D., Sligar, J.M. et al. 
(2011) SCYX- 7158, an orally- active benzoxaborole for the treatment 
of stage 2 human African trypanosomiasis. PLoS Neglected Tropical 
Diseases, 5, e1151. https://doi.org/10.1371/journ al.pntd.0001151
Joshua, R., Obwolo, M., Bwangamoi, O. & Mandebvu, E. (1995) Resistance 
to diminazine aceturate by Trypanosoma congolense from cattle in the 
Zambezi Valley of Zimbabwe. Veterinary Parasitology, 60, 1– 6. https://
doi.org/10.1016/0304- 4017(94)00780 - g
Kennedy, P.G. (2019) Update on human African trypanosomiasis (sleep-
ing sickness). Journal of Neurology, 266, 2334– 2337. https://doi.
org/10.1007/s0041 5- 019- 09425 - 7
Landfear, S.M. (2008) Drugs and transporters in kinetoplastid proto-
zoa. In: Majumder, H.K. (Ed.) Drug targets in kinetoplastid parasites. 
Springer, pp. 22– 32. https://doi.org/10.1007/978- 0- 387- 77570 - 8_3
Lanham, S.M. & Godfrey, D. (1970) Isolation of salivarian try-
panosomes from man and other mammals using DEAE- 
cellulose. Experimental Parasitology, 28, 521– 534. https://doi.
org/10.1016/0014- 4894(70)90120 - 7
Lanteri, C.A., Tidwell, R.R. & Meshnick, S.R. (2008) The mitochondrion 
is a site of trypanocidal action of the aromatic diamidine DB75 in 
bloodstream forms of Trypanosoma brucei. Antimicrobial Agents and 
Chemotherapy, 52, 875– 882. https://doi.org/10.1128/aac.00642 - 07
Lehane, M., Alfaroukh, I., Bucheton, B., Camara, M., Harris, A., Kaba, D. 
et al. (2016) Tsetse control and the elimination of Gambian sleeping 
sickness. PLoS Neglected Tropical Diseases, 10, e0004437. https://doi.
org/10.1371/journ al.pntd.0004437
Letunic, I. & Bork, P. (2018) 20 years of the SMART protein domain anno-
tation resource. Nucleic Acids Research, 46, D493– D496. https://doi.
org/10.1093/nar/gkx922
24  |     CARRUTHERS ET Al.
Lun, Z.- R., Lai, D.- H., Li, F.- J., Lukeš, J. & Ayala, F.J. (2010) Trypanosoma 
brucei: two steps to spread out from Africa. Trends in Parasitology, 26, 
424– 427. https://doi.org/10.1016/j.pt.2010.05.007
Luo, S., Rohloff, P., Cox, J., Uyemura, S.A. & Docampo, R. (2004) 
Trypanosoma brucei plasma membrane- type Ca2+- ATPase 1 
(TbPMC1) and 2 (TbPMC2) genes encode functional Ca2+- ATPases 
localized to the acidocalcisomes and plasma membrane, and essen-
tial for Ca2+ homeostasis and growth. Journal of Biological Chemistry, 
279, 14427– 14439.
Mamoudou, A., Delespaux, V., Chepnda, V., Hachimou, Z., Andrikaye, 
J.P., Zoli, A. et al. (2008) Assessment of the occurrence of trypano-
cidal drug resistance in trypanosomes of naturally infected cattle 
in the Adamaoua region of Cameroon using the standard mouse 
test and molecular tools. Acta Tropica, 106, 115– 118. https://doi.
org/10.1016/j.actat ropica.2008.02.003
Mamoudou, A., Zoli, A., Tanenbe, C., Andrikaye, J.P., Bourdanne, M.R., 
Marcotty, T. et al. (2006) Evaluation sur le terrain et sur souris de la 
résistance des trypanosomes des bovins du plateau de l'Adamaoua au 
Cameroun à l'acéturate de diminazène et au chlorure d'isométamid-
ium. Revue d’élevage et de Médecine Vétérinaire des Pays Tropicaux, 59, 
11– 16. https://doi.org/10.19182/ remvt.9948
Martin, M. (2011) Cutadapt removes adapter sequences from high- 
throughput sequencing reads. EMBnet Journal, 17(1), 10– 12. https://
doi.org/10.14806/ ej.17.1.200
Mäser, P., Sütterlin, C., Kralli, A. & Kaminsky, R. (1999) A nucleoside trans-
porter from Trypanosoma brucei involved in drug resistance. Science, 
285, 242– 244. https://doi.org/10.1126/scien ce.285.5425.242
Mathis, A.M., Bridges, A.S., Ismail, M.A., Kumar, A., Francesconi, I., 
Anbazhagan, M. et al. (2007) Diphenyl furans and aza analogs: ef-
fects of structural modification on in vitro activity, DNA binding, 
and accumulation and distribution in trypanosomes. Antimicrobial 
Agents and Chemotherapy, 51, 2801– 2810. https://doi.org/10.1128/
AAC.00005 - 07
Mathis, A., Holman, J.L., Sturk, L.M., Ismail, M.A., Boykin, D.W., Tidwell, 
R.R. et al. (2006) Accumulation and intracellular distribution of anti-
trypanosomal diamidine compounds DB75 and DB820 in African try-
panosomes. Antimicrobial Agents and Chemotherapy, 50, 2185– 2191. 
https://doi.org/10.1128/AAC.00192 - 06
Matovu, E., Stewart, M.L., Geiser, F., Brun, R., Mäser, P., Wallace, L.J.M. 
et al. (2003) Mechanisms of arsenical and diamidine uptake and resis-
tance in Trypanosoma brucei. Eukaryotic Cell, 2, 1003– 1008. https://
doi.org/10.1128/ec.2.5.1003- 1008.2003
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., 
Kernytsky, A. et al. (2010) The genome analysis toolkit: a MapReduce 
framework for analyzing next- generation DNA sequencing data. 
Genome Research, 20, 1297– 1303. https://doi.org/10.1101/
gr.107524.110
Millan, C.R., Acosta- Reyes, F.J., Lagartera, L., Ebiloma, G.U., Lemgruber, 
L., Nué Martínez, J. et al. (2017) Functional and structural analysis of 
AT- specific minor groove binders that disrupt DNA- protein interac-
tions and cause disintegration of the Trypanosoma brucei kinetoplast. 
Nucleic Acids Research, 45, 8378– 8839. https://doi.org/10.1093/nar/
gkx521
Moreno, S.N.J. (1996) Pentamidine is an uncoupler of oxidative phos-
phorylation in rat liver mitochondria. Archives of Biochemistry and 
Biophysics, 326, 15– 20. https://doi.org/10.1006/abbi.1996.0041
Mulugeta, W., Wilkes, J., Mulatu, W., Majiwa, P.A., Masake, R. & Peregrine, 
A.S. (1997) Long- term occurrence of Trypanosoma congolense resis-
tant to diminazene, isometamidium and homidium in cattle at Ghibe, 
Ethiopia. Acta Tropica, 64, 205– 217. https://doi.org/10.1016/s0001 
- 706x(96)00645 - 6
Munday, J.C., Eze, A.A., Baker, N., Glover, L., Clucas, C., Aguinaga 
Andres, D. et al. (2014) Trypanosoma brucei aquaglyceroporin 2 is a 
high- affinity transporter for pentamidine and melaminophenyl arse-
nic drugs and the main genetic determinant of resistance to these 
drugs. Journal of Antimicrobial Chemotherapy, 69, 651– 663. https://
doi.org/10.1093/jac/dkt442
Munday, J.C., Rojas López, K.E., Eze, A.A., Delespaux, V., Van Den 
Abbeele, J., Rowan, T. et al. (2013) Functional expression of TcoAT1 
reveals it to be a P1- type nucleoside transporter with no capac-
ity for diminazene uptake. International Journal for Parasitology: 
Drugs and Drug Resistance, 3, 69– 76. https://doi.org/10.1016/j.
ijpddr.2013.01.004
Munday, J.C., Settimo, L. & De Koning, H.P. (2015) Transport proteins 
determine drug sensitivity and resistance in a protozoan parasite, 
Trypanosoma brucei. Frontiers in Pharmacology, 6, 32. https://doi.
org/10.3389/fphar.2015.00032
Munday, J.C., Tagoe, D.N., Eze, A.A., Krezdorn, J.A., Rojas López, K.E., 
Alkhaldi, A.A. et al. (2015) Functional analysis of drug resistance- 
associated mutations in the Trypanosoma brucei adenosine trans-
porter 1 (TbAT1) and the proposal of a structural model for the pro-
tein. Molecular Microbiology, 96, 887– 900. https://doi.org/10.1111/
mmi.12979
Ramakrishnan, S. & Docampo, R. (2018) Membrane proteins in trypano-
somatids involved in Ca2+ homeostasis and signaling. Genes, 9, 304. 
https://doi.org/10.3390/genes 9060304
Schindelin, J., Arganda- Carreras, I., Frise, E., Kaynig, V., Longair, M., 
Pietzsch, T. et al. (2012) Fiji: an open- source platform for biological- 
image analysis. Nature Methods, 9, 676– 682. https://doi.org/10.1038/
nmeth.2019
Schnaufer, A., Clark- Walker, G.D., Steinberg, A.G. & Stuart, K. (2005) The 
F1- ATP synthase complex in bloodstream stage trypanosomes has an 
unusual and essential function. EMBO Journal, 24, 4029– 4040.
Siheri, W., Zhang, T., Ebiloma, G.U., Biddau, M., Woods, N., Hussain, M.Y. 
et al. (2016) Chemical and antimicrobial profiling of propolis from 
different regions within Libya. PLoS One, 11, e0155355. https://doi.
org/10.1371/journ al.pone.0155355
Sinyangwe, L., Delespaux, V., Brandt, J., Geerts, S., Mubanga, J., Machila, 
N. et al. (2004) Trypanocidal drug resistance in eastern prov-
ince of Zambia. Veterinary Parasitology, 119, 125– 135. https://doi.
org/10.1016/j.vetpar.2003.11.007
Sow, A., Sidibé, I., Bengaly, Z., Marcotty, T., Séré, M., Diallo, A. et al. 
(2012) Field detection of resistance to isometamidium chloride and 
diminazene aceturate in Trypanosoma vivax from the region of the 
Boucle du Mouhoun in Burkina Faso. Veterinary Parasitology, 187, 
105– 111. https://doi.org/10.1016/j.vetpar.2011.12.019
Stewart, M.L., Krishna, S., Burchmore, R.J.S., Brun, R., De Koning, H.P., 
Boykin, D.W. et al. (2005) Detection of arsenical drug resistance in 
Trypanosoma brucei with a simple fluorescence test. The Lancet, 366, 
486– 487. https://doi.org/10.1016/s0140 - 6736(05)66793 - 1
Sutherland, I. & Holmes, P. (1993) Alterations in drug transport in resis-
tant Trypanosoma congolense. Acta Tropica, 54, 271– 278. https://doi.
org/10.1016/0001- 706x(93)90099 - w
Sutherland, I., Mounsey, A. & Holmes, P. (1992) Transport of isometamid-
ium (Samorin) by drug- resistant and drug- sensitive Trypanosoma con-
golense. Parasitology, 104, 461– 467. https://doi.org/10.1017/s0031 
18200 0063721
Sutherland, I., Peregrine, A., Lonsdale- Eccles, J. & Holmes, P. (1991) 
Reduced accumulation of isometamidium by drug- resistant 
Trypanosoma congolense. Parasitology, 103, 245– 251. https://doi.
org/10.1017/s0031 18200 0059527
Teka, I.A., Kazibwe, A.J.N., El- Sabbagh, N., Al- Salabi, M.I., Ward, C.P., 
Eze, A.A. et al. (2011) The diamidine diminazene aceturate is a sub-
strate for the high- affinity pentamidine transporter: implications 
for the development of high resistance levels in trypanosomes. 
Molecular Pharmacology, 80, 110– 116. https://doi.org/10.1124/
mol.111.071555
Tihon, E., Imamura, H., Van den Broeck, F., Vermeiren, L., Dujardin, J.- C. 
& Van Den Abbeele, J. (2017) Genomic analysis of Isometamidium 
Chloride resistance in Trypanosoma congolense. International Journal 
     |  25CARRUTHERS ET Al.
for Parasitology: Drugs and Drug Resistance, 7, 350– 361. https://doi.
org/10.1016/j.ijpddr.2017.10.002
Vickerman, K. (1969) The fine structure of Trypanosoma congolense in its 
bloodstream phase. Journal of Protozoology, 16, 54– 69. https://doi.
org/10.1111/j.1550- 7408.1969.tb022 33.x
Vincent, I.M., Creek, D., Watson, D.G., Kamleh, M.A., Woods, D.J., 
Wong, P.E. et al. (2010) A molecular mechanism for eflornithine re-
sistance in African trypanosomes. PLoS Path, 6, e1001204. https://
doi.org/10.1371/journ al.ppat.1001204
Vitouley, H.S., Mungube, E.O., Allegye- Cudjoe, E., Diall, O., Bocoum, 
Z., Diarra, B. et al. (2011) Improved PCR- RFLP for the detection of 
diminazene resistance in Trypanosoma congolense under field condi-
tions using filter papers for sample storage. PLoS Neglected Tropical 
Diseases, 5, e1223. https://doi.org/10.1371/journ al.pntd.0001223
Wallace, L.J., Candlish, D. & De Koning, H.P. (2002) Different sub-
strate recognition motifs of human and trypanosome nucleobase 
transporters selective uptake of purine antimetabolites. Journal of 
Biological Chemistry, 277, 26149– 26156. https://doi.org/10.1074/jbc.
m2028 35200
Ward, C.P., Wong, P.E., Burchmore, R.J., De Koning, H.P. & Barrett, M.P. 
(2011) Trypanocidal furamidine analogues: influence of pyridine ni-
trogens on trypanocidal activity, transport kinetics, and resistance 
patterns. Antimicrobial Agents and Chemotherapy, 55, 2352– 2361. 
https://doi.org/10.1128/aac.01551 - 10
Wilkes, J.M., Mulugeta, W., Wells, C. & Peregrine, A.S. (1997) Modulation 
of mitochondrial electrical potential: a candidate mechanism for drug 
resistance in African trypanosomes. Biochemical Journal, 326, 755– 
761. https://doi.org/10.1042/bj326 0755
Zoltner, M., Campagnaro, G.D., Taleva, G., Burrell, A., Cerone, M., Leung, 
K.- F. et al. (2020) Suramin exposure alters cellular metabolism and 
mitochondrial energy production in African trypanosomes. Journal 
of Biological Chemistry, 295, 8331– 8347. https://doi.org/10.1074/jbc.
RA120.012355
Zoltner, M., Horn, D., De Koning, H.P. & Field, M.C. (2016) Exploiting 
the Achilles’ heel of membrane trafficking in trypanosomes. Current 
Opinion in Microbiology, 34, 97– 103. https://doi.org/10.1016/j.
mib.2016.08.005
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the 
Supporting Information section.
How to cite this article: Carruthers LV, Munday JC, Ebiloma 
GU, et al. Diminazene resistance in Trypanosoma congolense is 
not caused by reduced transport capacity but associated 
with reduced mitochondrial membrane potential. Mol 
Microbiol. 2021;00:1– 25. https://doi.org/10.1111/mmi.14733
